Synthesis and Characterization of Novel 2-Acyl-3-trifluoromethylquinoxaline 1,4-Dioxides as Potential Antimicrobial Agents

Galina I. Buravchenko 1, Dmitry A. Maslov 2, Md Shah Alam 3,4,5,6, Natalia E. Grammatikova 1, Svetlana G. Frolova 2,7, Aleksey V. Vatlin 2,8, Xirong Tian 3,4,5,6, Ivan V. Ivanov 1,9, Olga B. Bekker 2, Maxim A. Kryakvin 10, Olga A. Dontsova 10,11,12, Valery N. Danilenko 2, Tianyu Zhang 3,4,5,6, and Andrey E. Shchekotikhin 1,10

Abstract: The emergence of drug resistance in pathogens leads to a loss of effectiveness of antimicrobials and compounds the treatment of bacterial infections. Quinoxaline 1,4-dioxides represent a prospective scaffold for search of new compounds with improved chemotherapeutic characteristics. Novel 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides with alteration of substituents at position 2 and 6 were synthesized via nucleophilic substitution with piperazine moiety and evaluated against a broad panel of bacteria and fungi by measuring their minimal inhibitory concentrations. Their mode of action was assessed by whole-genomic sequencing of spontaneous drug-resistant mutants; followed by comparative genomic analysis, and on an original pDualrep2 system. Most of the 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides showed high antibacterial properties against Gram-positive strains, including mycobacteria, and the introduction of a halogen atom in the position 6 of the quinoxaline ring further increased their activity, with 13c being the most active.

Keywords: 3-trifluoromethylquinoxaline 1,4-dioxides; antimicrobial activity; M. smegmatis mutants; DNA-damaging agents; structure–activity relationships
1. Introduction

Bacterial infections have represented one of the most serious dangers to human health and animal husbandry throughout time. Currently there are over 12 classes of pathogenic bacteria, that cause various infectious diseases, which are considered as an increasing threat to human health due to their emerging resistance to most of antibacterial drugs, indicating the need for the development of novel agents for treating these drug-resistant bacteria [1]. Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and even fatal infections, being a particular threat to people with weak or immature immunity, such as the newborn, the elderly, and patients with oncology or AIDS [2]. In addition, the emergence and spread of antibiotics-resistant pathogens limit the possibilities for treating infections. A particularly alarming tendency is the spread of multidrug- and totally drug-resistant bacteria (the so-called “superbugs”), which cause infections that cannot be treated with any of the existing antimicrobial drugs [3].

Tuberculosis (TB), caused by Mycobacterium tuberculosis, considered as the leading killer among bacterial infections caused by a single agent, is another example of a high spread of drug resistance. While the overall numbers of incidence and mortality are slowly decreasing throughout the years, the numbers of multidrug-resistant (MDR-TB, resistant to isoniazid and rifampicin) and extensively drug-resistant TB (XDR-TB, defined as MDR-TB with additional resistance to a fluoroquinolone and a second-line injectable drug) are constantly growing, representing a threat to global TB control [4]. Thus, search for alternatives to the currently used antimicrobial drugs, subjected to a loss of effectiveness due to the emergence of drug resistance, including targeted synthesis of new potential antibacterial agents is a hot topic direction in medicinal chemistry.

Quinoxaline 1,4-dioxides are an important class of heterocyclic compounds which are constantly in focus of medicinal chemists. The properties of quinoxaline 1,4-dioxides, which have a wide spectrum of biological activity, including antimicrobial, antiproliferative, antifungal, antiprotozoal, anti-inflammatory, and antioxidant activities, have been actively studied for more than five decades [5,6]. Due to their ability to undergo bioreductive activation, these derivatives are of great interest for a broad application in human and veterinary medicine.

The antibacterial activity of quinoxaline 1,4-dioxides has been known since the 1940s and they have also been used as growth stimulants which improve feed conversion efficiency in animal husbandry [7,8]. Carbadox (CARB, Figure 1, 1) is an approved veterinary antibacterial agent used in the United States as a feed additive for the control and prevention of swine dysentery, helminthiasis and enteritis [5,9]. 2,3-Bis(hydroxymethyl)quinoxaline 1,4-dioxide (dioxidine, DIOX, 2, Figure 1) is another derivative of quinoxaline 1,4-dioxide, which has found an application in the medical practice as effective antibacterial drug with a broad spectrum of antimicrobial activity [10]. Moreover, some quinoxaline 1,4-dioxides have demonstrated promising anti-yeast activity on Candida albicans, C. glabrata, C. krusei, Saccharomyces cerevisiae and the clinically important C. parapsilosis [11].

In the last two decades, several series of quinoxaline 1,4-dioxides have been evaluated and showed potent antibacterial activity, including activity against M. tuberculosis strains.
with MDR [12–16]. Previously, Monge et al. reported potential antitubercular quinoxaline 1,4-dioxide derivatives (Figure 1, compounds 3a–c), which demonstrated activity against non-replicating mycobacteria responsible for the long-lasting courses of antitubercular therapy [17]. Nevertheless, the potential impact of the various substituents in quinoxaline nucleus on antimycobacterial activity requires further assessment.

Thereby, quinoxaline 1,4-dioxide is a prospective scaffold for further development of new antimicrobial drugs with improved efficacy as well as lowered toxicity. Chemical modification of function groups attached to the quinoxaline scaffold is one of the methods for modulating its pharmacological properties. However, despite the great attention to bioactive quinoxaline 1,4-dioxides, the 6(7)-amino derivatives and their antimicrobial activity have not yet been studied. The trifluoromethyl group is one of the privileged structural fragments in medicinal chemistry which is used for modulating the pharmacological properties of molecules due to its unique characteristics such as molecular volume, lipophilicity, and the ability to form hydrogen bonds [18,19]. It has been previously revealed that the introduction of the trifluoromethyl group also significantly increased anti-mycobacterial activity of quinoxaline 1,4-dioxide derivatives [20]. Therefore, we assume that the introduction of a trifluoromethyl group into the structure of quinoxaline 1,4-dioxides can significantly increase both the binding to cellular targets and intracellular penetration of such derivatives. We report a series of water-soluble 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxide derivatives with a variety of substituents at positions 2 and 6, which were synthesized and tested against a panel of pathogenic fungi, Gram-negative and Gram-positive bacteria, including Mycobacterium species.

2. Results and Discussion
2.1. Chemistry

It was previously shown that the halogen atoms in the phenyl ring of the quinoxaline 1,4-dioxide activated for nucleophilic substitution due to electron-withdrawing effects of heterocyclic moiety and attached substituents. This property may be efficiently used for a modulation of the properties of quinoxaline 1,4-dioxides [21]. Therefore, we applied this approach for the diversification of halogen-substituted 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides. Synthesis of several starting halogen-substituted 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides (e.g., 5a–c, 6a–c) via the Beirut reaction has been described earlier [22–25]. According to this method, condensation of benzofuroxans 4a–d [26,27] with trifluoromethylsubstituted 1,3-dicarbonyl compounds, which was performed in dry chloroform in the presence of triethylamine, led to a series of key 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides 5–6a–c, 7a–d and 8–11a–c. Due to the tautomeric equilibrium in monosubstituted benzofuroxans, the two regioisomers of 6(7)-substituted quinoxaline 1,4-dioxides can be formed in the Beirut reaction, and their ratio strongly depends on the electronic effects of the substituents [28]. However, the reaction of the fluorine derivative 4a with dicarbonyl compounds led exclusively to one quinoxaline derivative in all cases. Therefore, the position of the fluorine atom in the products obtained from fluorobenzofuroxan 4a was fixedly examined. The analysis of $^{13}$C-NMR spectra was one of the reliable ways to determine the position of substituents in regioisomeric 6(7)-substituted quinoxaline 1,4-dioxides [28]. A comparison of the chemical shifts in the spectra of the paternal 2-propionyl-3-trifluoromethylquinoxaline 1,4-dioxide (7d) and its fluoro derivative 7a revealed changes of the chemical shifts of bridging carbon atoms at the positions 9 and 10 of quinoxaline 7a that corresponded to the described increments values ($I_C$) [29] for the fluorine atom located at position 7 (Supplementary Material, Figures S3–S56; Table S1). It was therefore concluded that the assigned structure of the derivatives 5–11a (Scheme 1) showed a high regioselectivity of the Beirut reaction in the case of trifluoromethylsubstituted 1,3-dicarbonyl compounds with monosubstituted benzofuroxans.
It was therefore concluded that the assigned structure of the derivatives showed a high regioselectivity of the Beirut reaction in the case of trifluoromethylsubstituted 1,3-dicarbonyl compounds with monosubstituted benzofuroxans.

Scheme 1. Synthesis of starting compounds 5–6a–c, 7a–d and 8–11a–c. Reagents and Conditions: (a) N-Boc-piperazine, THF, TEA, r.t., 4–8 h, 58–96%; (b) HCl/Et2O, THF, r.t., 42–91%.

The piperazine ring is a structural fragment of a lot of drugs actively applied in the medicine and veterinary. Thus, piperazine moiety has an important role in antimicrobial properties of fluoroquinolone antibiotics such as Ciprofloxacin and their analogues. This cyclic diamine and its derivatives were efficiently used as the N-nucleophiles for the diversification of the quinoxaline scaffolds and preparation of water-soluble derivatives with promising anticancer potencies [21,31]. However, attempts to carry out the nucleophilic substitution of the halogen atom on the quinoxaline core of 5–11a–c by piperazine in DMF as described earlier [21] were ineffective due to the formation of a mixture of deoxygenated analogs as the main products of the reaction. A similar observation was made for several reactions of 3-trifluoromethylquinoxalines with different amines [32,33]. In addition, the isolation and purification of the target aminoderivatives were complicated by a higher water-solubility of their free bases as compared to the previously reported aminooximinoquinoline 1,4-dioxides.

Nevertheless, the use of N-Boc-piperazine in this reaction was found to be more effective and reduced side products of the halogen substitution in quinoxaline ring of 3-trifluoromethylquinoxaline 1,4-dioxides 5–11. Additionally, the protective group simplified the isolation and a chromatographic purification of formed Boc-derivatives 12–18 (Scheme 2). The optimization of the reaction conditions including a variation of solvents, bases and the ratios of the reagent, allowed us for additionally increase the yields of Boc-derivative 12–18 by 20–40%. Thus, the treatment of derivatives 5–11a–c with a threefold excess of N-Boc-piperazine in THF in the presence of the TEA at room temperature produced Boc-derivative of 12–18a–c in good yields. The purified Boc- intermediates 12–18a–c were transformed into the target hydrochlorides of amino-derivatives 12–18a–c by the treatment with hydrogen chloride in ether (Scheme 2).

Scheme 2. Synthesis of 7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-dioxides 12–19a–c. Reagents and Conditions: (a) N-Boc-piperazine, THF, TEA, r.t., 4–8 h, 58–96%; (b) HCl/Et2O, THF, r.t., 42–91%.

It should be noted that the treatment of the 6,7-dihalogeno-3-trifluoromethylquinoxaline 1,4-dioxides 5–11b–c with N-Boc-piperazine resulted in the formation of predominantly...
7-aminoderivatives 12–18b–c. The position of the amino group in the quinoxaline ring of 12–18 was confirmed by analysis of the $^{13}$C-NMR spectra and the increment values for the chemical shifts. As mentioned above, the position of the substituents in the benzene ring of the quinoxaline has a significant effect on the chemical shifts of the signals of the pyrazine core in the $^{13}$C-NMR spectra. The comparison of the $^{13}$C-NMR spectra of 2-propionyl-3-trifluoromethylquinoxaline 1,4-dioxide (7d) and its amino derivatives 14a–c showed that the largest changes in the chemical shift of carbon atoms were observed at positions 3 and 10 of the quinoxaline nucleus due to the conjugation with the amino group. The observed changes corresponded to the increments ($\Delta C$) of the tertiary amino group in the $^{13}$C-NMR spectra of arenes [29,34] and well correlated to the data for previously described amino derivatives of quinoxaline 1,4-dioxides [21,31] (Supplementary Material, Figures S5–S54; Table S1). The structure of the obtained derivatives 14b–c revealed that the halogen atoms at positions 6 and 7 of the starting compounds 5–11b–c differed in the reactivity for the nucleophilic substitution. Thus, we assume, that the observed preferable substitution of the halogen atom at position 7 of 6,7-dihalogeno-3-trifluoromethylquinoxaline 1,4-dioxides 5–11b–c is associated with a highest electron-withdrawing character of the trifluoromethyl group at position 3 in comparison with acyl groups at position 2 of the heterocycle that leads to formation of a more stable intermediate Mesenheimer complex. The structures of compounds 13b and 13c were additionally proven by 2D NMR techniques including HSQC and HMBC experiments (Supplementary Material, Figures S57–S60): the presence of key four-bond correlations in the CIGAR-HMBC spectra between the signals of H-8 and C-2 observed for derivatives 13b and 13c confirmed the assigned structures of these compounds (Supplementary Material, Figures S58 and S60). It should be noted that the obtained results do not agree with the data of Zhang et al. [35], who described an analogue of compound 12b, with the piperazine residue at the position 6 of heterocycle. However, the amine disposition was not justified in this work.

Along with the notable general instability of the obtained aminoderivatives of 3-trifluoromethylquinoxaline 1,4-dioxides 12–18, compounds 15–18 with aroyl groups in the position 2 were the most unstable in this series under the reaction conditions, and during their isolation and purification. This partly explains the low yields of these derivatives. Moreover, in the case of 7-amino-2-aryl-6-fluoro-3-trifluoromethylquinoxaline 1,4-dioxides 15–18b, the fluorine atom at position 6 of the quinoxaline ring also retained the ability for nucleophilic substitution reactions. Thereby, the synthesis of these compounds alone to the target Boc-derivatives 15–18b led to disubstitution byproducts 15–18d (Figure 2) which were isolated as dihydrochlorides in 15–41% yields. The observed highest reactivity of the fluorine atom at position 6 of quinoxaline 1,4-dioxide 15–18b in comparison to congeners 12–14b in the substitution reaction could be explained by the biggest electron-withdrawing effect of the aroyl groups at position 2 of the quinoxaline ring of these derivatives.

![Figure 2. Structures of byproducts quinoxaline 1,4-dioxides 15–18d.](image)

We have earlier developed an original scheme for the synthesis of 7-aminoquinoxaline-2-carbonitrile 1,4-dioxides based on the Beirut reaction of 5-aminosubstituted benzofuroxans and benzoylacetonitrile, which proceeded with a good regioselectivity [31]. Considering this data, we tested the possibilities of this approach for the synthesis of congeners with 3-trifluoromethyl group, so a tentative heterocyclization of the previously described
5-(Boc-piperazin-1-yl)-6-chlorobenzofuroxan 19 [31] with 1,1,1-trifluorohexane-2,4-dione in THF in the presence of the triethylamine led to a formation of the derivative of quinoxaline 1,4-dioxide in a good yield (Scheme 3). The obtained by this scheme compound had physicochemical and spectral characteristics identical to derivative 14c, synthesized by the nucleophilic substitution of the chlorine atom of quinoxaline 1,4-dioxide 7c (Scheme 2). Thus, this alternative approach also led to 7-amino derivatives 3-trifluoromethyl quinoxaline 1,4-dioxides, however, the first one looking more preferable, since it opens up more opportunities for diversification of the scaffold on the final steps of the synthesis.

Scheme 3. The alternative way of synthesis of the 7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-dioxide 14c. Reagents and Conditions: (a) 1,1,1-trifluoro-2,4-hexanedione, THF, Et3N, r.t., 5 h, 81%; (b) HCl/Et2O, THF, r.t., 76%.

All synthesized compounds 12–18 were characterized by NMR spectra, HRMS and UV spectra; the HPLC-determined purity was ≥ 95% (Supplementary Materials, Figures S1–S12; Table S1).

2.2. Biological Screening

The antibacterial activity of a novel 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxides 12–18 was evaluated against a panel of bacterial strains, including Gram-positive (S. aureus ATCC 29213, S. epidermidis ATCC 14990, E. facalis ATCC 29212, M. smegmatis mc2 155, M. tuberculosis AIRa and M. tuberculosis UAIRv) and Gram-negative bacteria (E. coli ATCC 25922, K. pneumoniae 1951, P. aeruginosa ATCC 27853). The antifungal activity was evaluated against C. albicans ATCC 10231 and M. canis B-200. The minimum inhibitory concentration (MIC) values of 12–18 and reference drugs are summarized in Table 1. DIOX was used as the main reference derivative of quinoxaline 1,4-dioxide used in the clinic, amphoterocin B (AMPH) was used as a standard for the evaluation of antifungal activity, and rifampicin (RIF) and ciprofloxacin (CIP) for the antibacterial activity.

The structure and antibacterial activity of the 25 novel compounds are shown in Table 1. Eight derivatives out of the series (compounds 12c, 13c, 14c, 15b, 15c, 16c, 17c and 18b) had the highest activities against most of the tested microorganisms. It is worth noting that the MIC values of all the obtained compounds were noticeably lower than those of the reference drug DIOX. Furthermore, in some cases the obtained derivatives (for example, compounds 13c, 15c, 16c and 18b) have demonstrated similar antimicrobial potencies as compared to the reference antibiotics such as CIP, AMPH and RIF, but in general they had a lower activity against the tested cultures. Most of the compounds exhibited a promising activity on Gram-positive strains but were less effective on Gram-negative bacteria and fungi. However, the promising antibacterial activity on E. coli ATCC 25922 and K. pneumoniae 1951 was observed for the derivatives 12a, 13a–c and 14b which have the MIC values in the range of 2–16 µg/mL. Also, the compounds 12c, 15b and 18b–d have a comparable antifungal activity to AMPH (MIC = 4–16 and 0.75–2 µg/mL respectively) on C. albicans ATCC 10231 and M. canis B-200. P. aeruginosa ATCC 27853 was the least susceptible to the synthesized compounds. The lower activity observed on Gram-negative strains, with the exception of E. coli ATCC 25922, might be possibly caused by the lipopolysaccharide component of their cell wall, the lower permeability of the outer membrane, or some metabolic differences between these two phyllogenetic groups, that provides the resistance to the compounds. At the present time, there is no evidence that could explain why some quinoxaline derivatives have differences in G+ and G− inhibition [36].
Table 1. Structures and antimicrobial activity * (MIC, μg/mL) of 3-trifluoromethylquinoxaline 1,4-dioxides 12–18 for tested microorganisms.

![Chemical Structure](image)

| Cmpnd | R<sup>1</sup> | R<sup>2</sup> | M. smegmatis mc<sup>2</sup>155 | M. tuberculosis ATCC 27213 | S. aureus ATCC 29213 | S. epidermidis ATCC 19990 | E. coli ATCC 29212 | K. pneumoniae FC1 | P. aeruginosa ATCC 27853 | C. albicans ATCC 10231 | M. canis B-200 |
|-------|-------------|-------------|-----------------------------|--------------------------|----------------------|--------------------------|-----------------|-----------------|----------------------|----------------------|------------------|
| 12a   | OEt         | H           | 4                           | 20                       | 20                   | 4                        | 2               | 8               | 4                    | 16                   | >32              |
| 12b   | OEt         | F           | 8                           | −                        | −                     | 8                        | 4               | 8               | 32                   | >32                  | >32              |
| 12c   | OEt         | Cl          | 4                           | >20                      | 10                   | 2                        | 0.5             | 2               | 32                   | >32                  | >32              |
| 13a   | Me          | H           | 4                           | 20                       | 20                   | 4                        | 2               | 4               | 8                    | >32                  | >32              |
| 13b   | Me          | F           | 8                           | 4                        | 10                   | 5                        | 1               | 0.25            | 0.5                 | 2                    | 8                |
| 13c   | Me          | Cl          | 4                           | 10                       | 5                    | 1                        | 0.25            | 0.5             | 2                    | 8                    | 32               |
| 14a   | Et          | H           | 2                           | 20                       | 20                   | 2                        | 2               | 4               | 8                    | 32                   | >32              |
| 14b   | Et          | F           | 8                           | 20                       | 20                   | 2                        | 1               | 2               | 4                    | 16                   | >32              |
| 14c   | Et          | Cl          | 8                           | >20                      | 10                   | 2                        | 1               | 2               | 8                    | >32                  | >32              |
| 15a   | Ph          | H           | 8                           | −                        | −                     | 8                        | 4               | 4               | 32                   | >32                  | >32              |
| 15b   | Ph          | F           | 8                           | 10                       | 5                    | 2                        | 0.5             | 1               | 16                   | >32                  | >32              |
| 15c   | Ph          | Cl          | 8                           | 10                       | 5                    | 2                        | 0.25            | 1               | 32                   | >32                  | >32              |
| 15d   | Ph          | Cl          | 8                           | 10                       | 5                    | 2                        | 0.25            | 1               | 32                   | >32                  | >32              |
| 16a   | 2-Furyl     | H           | 8                           | >32                      | >20                  | >20                      | 4               | 2               | 4                    | 32                   | >32              |
| 16b   | 2-Furyl     | F           | 8                           | 20                       | 10                   | 2                        | 0.5             | 1               | 8                    | 32                   | >32              |
| 16c   | 2-Furyl     | Cl          | 4                           | 20                       | 10                   | 1                        | 0.5             | 1               | 8                    | >32                  | >32              |
| 17a   | 2-Tieryl    | H           | 8                           | −                        | −                     | 16                        | 4               | 16              | >32                  | >32                  | >32              |
| 17b   | 2-Tieryl    | F           | 16                          | −                        | −                     | 2                        | 1               | 1               | >32                  | >32                  | >32              |
| 17c   | 2-Tieryl    | Cl          | 8                           | −                        | −                     | 2                        | 0.5             | 1               | >32                  | >32                  | >32              |
| 17d   | 2-Tieryl    | H           | 16                          | −                        | −                     | >32                       | 32              | 32              | >32                  | >32                  | >32              |
| 18a   | 2-Naphthyl  | H           | 4                           | −                        | −                     | 16                        | 4               | 8               | >32                  | >32                  | >32              |
| 18b   | 2-Naphthyl  | F           | 8                           | −                        | −                     | 2                        | 0.5             | 2               | >32                  | >32                  | >32              |
| 18c   | 2-Naphthyl  | Cl          | 32                          | −                        | −                     | 8                        | 4               | 4               | >32                  | >32                  | >32              |
Table 1. Cont.

| Cmpnd | R<sup>1</sup> | R<sup>2</sup> | Strain/MIC (Minimum Inhibitory Concentration, μg/mL) * |
|-------|--------------|--------------|-----------------------------------------------------|
| 18d   | 2-Naphtyl    |              | M. smegmatis mc<sup>2</sup> 32 10 20 0.125 0.006 0.25 0.125 0.75 2 |
|       |              |              | M. tuberculosis UAlRv 32 12 >32 12 >32 12 >32 12 >32 12 >32 |
|       |              |              | S. aureus ATCC 29213 8 4 16 32 32 4 16 |
|       |              |              | S. epidermidis ATCC 14990 32 32 32 32 32 32 32 |
|       |              |              | E. faecalis ATCC 29212 16 8 32 32 32 32 32 |
|       |              |              | K. pneumonia ATCC 1951 16 |
|       |              |              | P. aeruginosa ATCC 27853 16 |
|       |              |              | C. albicans ATCC 10231 16 |
|       |              |              | M. genitalium B-200 16 |

* MICs are presented as modal values for 3–5 independently replicated MIC tests for each strain and for the antibiotics.

Analysis of the activity data presented in Table 1 reveals that the substitution of both halogen atoms, in positions 6 and 7 of the quinoxaline ring, by a cyclic diamine moiety led to a decrease of the antimicrobial activity of the derivatives 15–19d against all tested strains. For instance, the derivatives of 6,7-diamino-3-trifluoromethylquinoxaline 1,4-dioxides 15–19d displayed 2–8 times lower MIC values than their mono-amino analogs 15–19a. At the same time, activity of the compound 18d was similar to that of its mono- and halogen-substituted analogs 18a–c. Regarding the type of the substituent at position 2 of quinoxaline, the derivatives with alkylcarbonyl- and alkoxy carbonyl groups (compounds 12–14) slightly stand out in terms of MIC values compared to the compounds with aroyl and heteroaroyl groups in this position (derivatives 15–18 respectively). If considering aroyl groups at this position when the benzoyl is substituted by its heterocyclic biososteres (with furyl, thieryl) or naphthoyl moiety no principal changes in antimicrobial activity have been observed. Therefore, it can be concluded that the substituents on position 2 of the quinoxaline ring do not play an important role in antimicrobial activity. It is noteworthy that the most crucial structural requirement, is the presence of the halogen atom in position 7 of quinoxaline scaffold. In general, the highest antimicrobial activity in all the tested strains was shown by derivatives with a chlorine in 6 position of quinoxaline ring (compounds 12–18c). It should be noted that the analogue of the synthesized derivatives, the reference drug DIOX, showed no activity in concentrations < 32 μg/mL against all tested microorganisms. Most of the derivatives demonstrated moderate to no antimycobacterial activity, however the compounds 12a, 12c, 13a, 13c, 14a, 16c and 18a presented the same inhibitory effect as rifampicin (RIF) on M. smegmatis mc<sup>2</sup> 155 (MIC = 4 μg/mL), while the compounds 13b–c and 15b–c showed promising activity on M. tuberculosis strains with MIC values 5–10 μg/mL. The compound 13c showed the highest activity against all tested microorganisms with the exception of P. aeruginosa ATCC 27853 strain with MIC values between 0.25 and 10 μg/mL.

2.3. Mechanism of Action Determination

As it has been previously shown, that DIOX induces SOS-response in bacterial cells [37], the mechanism of antibacterial activity of novel 3-trifluoromethylquinoxaline 1,4-dioxides was analyzed by means of the pDualrep2 reported system [38]. In this reporter expression, turboRFP gene is under regulation of sulA promoter and upregulated in the presence of SOS-response inducers (topoisomerase inhibitors, DNA-intercalators etc), while
is expressed in the presence of translation inhibitors, due to the stalling of the ribosomes at the modified TrpL leader peptide which leads to transcription antitermination.

The obtained results, presented in Figure 3, show that most of the new derivatives of 3-trifluoromethylquinoxaline 1,4-dioxide 12–15 as well as reference drug DIOX strongly caused DNA damage and induced SOS response in *E. coli* BW25513 strain, which corresponded with previous report of a DNA damaging mode of action of quinoxaline 1,4-dioxides induced by oxidative stress in pathogens [39]. Comparison of responses to DNA-damage between the DIOX and the new quinoxaline 1,4-dioxides showed that induction of the bacterial SOS-response for DIOX was more pronounced than the one for the compounds 12a, 12c, 13–15a–c, 16b, 16c, 17a–c and 18b, however the majority of its analogues had a superior antibacterial activity. Additionally, as shown in Figure 3, the derivatives 13a–c expressed both turboRFP and Katushka2S fluorescence proteins and may have a dual mechanism of action via DNA-damage and blocking of protein synthesis in bacterial cells. Interestingly, several compounds which have a noticeable antibacterial activity (e.g., 12b, 15d, 18d) did not induce SOS-response or inhibition of protein synthesis, and so may act on bacteria via independent mechanisms and have an alternative bacterial target.

Thereby, a primary analysis of structure-activity relationships and results of pDualrep2 assay revealed that the effect of 3-trifluoromethylquinoxaline 1,4-dioxide derivatives on bacterial cells is not limited to the action on DNA and can have a multitarget character.

2.4. *M. smegmatis* Drug-Resistant Mutants and Their Analysis

The analysis of spontaneous drug-resistant mutants is a classic approach aimed at shedding additional light on the mechanisms of action and drug-resistance: mutations

**Figure 3.** Agar plate coated with a layer of *E. coli* BW25513 reporter strain of that was transformed by plasmid pDualrep2. 1 μL of 20 μg/mL solution for all tested compounds were spotted on the plate, except for levofloxacin (Lev)—50 μg/mL and erythromycin (Ery)—50 μg/mL. Cells with tested compounds were identified by white number. The plate was scanned in the Cy3 and Cy5 channels to determine turboRFP and Katushka2S fluorescence, respectively, and showed a combined image where turboRFP and Katushka2S fluorescence was shown in green and red hues, respectively. Fluorescence of turboRFP protein indicates DNA-damage SOS-response, while Katushka2S indicates translation inhibition.
may occur in genes, encoding drug-targets, pro-drug activators, efflux-pumps, transcriptional regulators, proteins affecting cell wall permeability, etc., leading to drug resistance, and even cross-resistance with other drugs. We were able to obtain \textit{M. smegmatis} mc\textsuperscript{2} 155 spontaneous mutants resistant to 4 × MIC of compounds \textbf{16b} and \textbf{15b} at a frequency of $3.6 \times 10^{-8}$ and $5.0 \times 10^{-8}$, respectively. We have selected 3 mutants, resistant to each compound (\textit{M. smegmatis tfqR1}, \textit{tfqR2} and \textit{tfqR4} obtained on \textbf{16b}, and \textit{M. smegmatis tfqR5}, \textit{tfqR6} and \textit{tfqR7} obtained on \textbf{15b}) for further analysis.

The mutants obtained on \textbf{16b} were cross-resistant to the majority of the tested compounds, with \textit{M. smegmatis tfqR1} being the most resistant one, while those obtained on \textbf{15b} were only resistant to part of the compounds with just a slight increase in MIC level (Table 2).

### Table 2. MIC values of the tested compounds on \textit{M. smegmatis} spontaneous mutants.

| Cmpnd | mc\textsuperscript{2} 155 | \textit{tfqR1} | \textit{tfqR2} | \textit{tfqR4} | \textit{tfqR5} | \textit{tfqR6} | \textit{tfqR7} |
|-------|-----------------|---------|---------|---------|---------|---------|---------|
| \textbf{12a} | 4                | >32     | >32     | >32     | 16      | 8       | 8       |
| \textbf{13a} | 4                | >32     | 32      | 16      | 16      | 4       | 4       |
| \textbf{13b} | 4                | >32     | 32      | 16      | 16      | 8       | 8       |
| \textbf{13c} | 4                | >32     | 32      | 16      | 16      | 16      | 8       |
| \textbf{15a} | 8                | >32     | >32     | >32     | 8       | 8       | 16      |
| \textbf{15b} | 8                | >32     | >32     | >32     | 8       | 16      | 16      |
| \textbf{15c} | 8                | >32     | >32     | >32     | 8       | 16      | 16      |
| \textbf{15d} | 8                | >32     | >32     | 32      | 8       | 8       | 8       |
| \textbf{16b} | 8                | >32     | 32      | 8       | >32     | 8       | 16      |
| \textbf{16c} | 8                | >32     | >32     | 32      | 8       | 8       | 8       |
| \textbf{17a} | 16               | >32     | 16      | 32      | 8       | 16      | 8       |
| \textbf{17b} | 16               | >32     | 16      | 32      | 8       | 16      | 8       |
| \textbf{17c} | 8                | >32     | 16      | >32     | 8       | 16      | 16      |
| \textbf{18a} | 8                | >32     | 32      | >32     | >32     | 16      | 16      |
| \textbf{DIOX} | 32               | >32     | 32      | >32     | >32     | >32     | 32      |

The whole-genomic sequencing revealed that mutants \textit{tfqR1}, \textit{tfqR2} and \textit{tfqR4} had 6–9 unique, non-synonymous mutations, and mutants \textit{tfqR5}, \textit{tfqR6} and \textit{tfqR7}–2–3 unique, non-synonymous mutations each (Supplementary Material, Table S2), supporting our data and the previous reports about quinoxaline 1,4-dioxides DNA-damaging properties [40,41].

One non-synonymous mutation was common for all the strains: a deletion of nine nucleotides (GCCGCTGCTGC) in \textit{MSMEG_4883}, resulting in a loss of three amino acids in the encoded AMP-dependent synthetase/ligase. We were able to construct the \textit{M. smegmatis} \textit{4883c} strain by homologous recombination, harboring this mutation alone. However, this strain was susceptible to all the compounds, suggesting that this single mutation is not directly involved in resistance to the tested compounds, or might require one of the additional mutations to result in a drug-resistant phenotype. It is worth-noting, that the deleted 9 nucleotides (CGCTGCTGC) were repeated three times within the \textit{MSMEG_4883} (Supplementary Material, Figure S113), thus making the spontaneous occurrence of this mutation more likely to happen under the DNA-damaging effect of quinoxaline 1,4-dioxides.

We have also observed a mutation in \textit{MSMEG_1380} in \textit{M. smegmatis} \textit{tfqR7}, encoding a TetR-family transcriptional repressor, which regulates the \textit{mmpS5-mmpL5} operon expression. Mutations in \textit{MSMEG_1380} lead to overexpression of \textit{mmpS5-mmpL5} (\textit{MSMEG_1381-MSMEG_1382}), resulting in enhanced efflux provided by the MmpS5-MmpL5 transporters [42]. The MmpS5-MmpL5 system is a multidrug resistance transporter, able to provide various mycobacterial species resistance to bedaquiline and clofazimine [43], azoles [44], thiacetazone derivatives [45], imidazo[1,2-b][1,2,4,5]tetrazines [46], and tryptanthrins [47]. The previously described recombinant \textit{M. smegmatis} \textit{atR9c} strain, with an incorporated frameshift mutation in \textit{MSMEG_1380} [42] revealed to be sensitive to most
of the tested compounds, though a 4-fold MIC increase was observed for compounds 13a, 13b and 18a. Only a 2-fold increase in MIC was observed for 15b on M. smegmatis atr9c, corresponding to the value on M. smegmatis tfqR7, which might be due to the differences of aeration in liquid and on solid media (used for MIC determination and mutants generation, respectively). Our data shows that the MmpS5-MmpL5 efflux might be structure-specific in regards to quinoxaline 1,4-dioxides, and act as a secondary mechanism of protection, providing a low level of resistance to some of the compounds.

Since quinoxaline 1,4-dioxides were shown to be redox-activated DNA-cleaving agents [41], some of the mutations in the resistant M. smegmatis mutants may lead to the disruption of the compounds activating enzymes. First of all, this refers to the non-synonymous single nucleotide polymorphisms (SNPs), observed in genes, encoding redox homeostasis enzymes, especially oxidases/oxidoreductases/dehydrogenases [39]. We observed nonsynonymous SNPs in MSMEG_0341, MSMEG_1497 and MSMEG_4323 (F420-dependent LLM class oxidoeductase, acyl-CoA dehydrogenase, and pyruvate dehydrogenase subunit E1, respectively) in M. smegmatis tfqR2, in MSMEG_4863 (LLM class flavin-dependent oxidoeductase) in M. smegmatis tfqR4, in MSMEG_0889 (succinate-semialdehyde dehydrogenase) in M. smegmatis tfqR6, and in MSMEG_6440 (monooxygenase, flavin-binding family protein) in M. smegmatis tfqR7. M. smegmatis tfqR1 harbored an SNP in MSMEG_1914, encoding the alternative sigma-factor SigH. Its homolog in M. tuberculosis has been shown to be induced by heat, oxidative and nitric oxide stresses, up-regulating a plethora of genes, including several oxidoreductases [47], thus the disruption of its function may lead to the downregulation of several genes, potentially involved in activation of quinoxaline 1,4-dioxides.

Mutations in MSMEG_4189 and MSMEG_6392, observed in M. smegmatis tfqR5 may probably have a direct or indirect protective effect on bacterial cells. MSMEG_4189 encodes the cysteinyl-tRNA synthetase, which is involved in mycothiol biosynthesis pathway in mycobacteria. Mycothiol acts as an electron acceptor/donor and serves as a cofactor in detoxification reactions for alkylating agents, free radicals and xenobiotics, maintaining the intracellular redox homeostasis [48]. MSMEG_6392 encodes the polyketide synthase Pks13, an enzyme which catalyzes the condensation reaction, which produces \( \alpha \)-alkyl-\( \beta \)-ketoacids, direct precursors of mycolic acids, thus being involved in cell wall biosynthesis [49]. The mutation in MSMEG_6392 could thus alter the permeability of the mycobacterial cell wall.

The number of unique mutations within a single strain correlated with the level of resistance, suggesting that their combination has a synergistic effect. However, the mutation in SigH might have the highest stand-alone effect for M. smegmatis tfqR1 due the downregulation of several oxidoeductases by its disruption, while the MSMEG_4863-encoded oxidoeductase, could have a higher impact in the activation of quinoxaline 1,4-dioxides alone, as compared to other redox-proteins, as its mutation led to a higher level of resistance, as compared to those in MSMEG_0889 and MSMEG_6440.

3. Materials and Methods

3.1. Synthesis

3.1.1. Materials and General Methods

NMR spectra of all synthesized compounds were recorded on a VXR-400 instrument (Varian, 3100 Hansen Way, Palo Alto, CA, USA) at 400 MHz (\(^1\)H-NMR) and 100 MHz (\(^13\)C-NMR). Chemical shifts were measured in DMSO-\(d_6\) using TMS as an internal standard. Analytical TLC was performed on silica gel F254 plates (Merck KGaA, 64271 Darmstadt, Germany) and column chromatography on Merck 60 Silica Gel. Melting points were determined on an SMP-20 apparatus (Büchi, CH-9230 Flawil 1, Flawil, Switzerland) and are uncorrected. High-resolution mass spectra were recorded by electron spray ionization on a micro OTOF-QII instrument (Bruker Daltonics, Bremen, Germany). UV spectra were recorded on a U2000 spectrophotometer (Unico, 182 Ridge Road, Dayton, USA) and IR spectra were recorded on i510 Fourier transform IR spectrometer (Nicolet, Madison, WI, USA). HPLC was performed using a Class-VP V6.12SP1 system (Shimadzu, Canby, Oregon, USA).
3.1.2. General Procedure for Synthesis of 5–6a–c, 7a–d and 8–11a–c

The compounds 5–6a–c, 7a–d and 8–11a–c were previously synthesized in [22–25]. The preparation of the compounds 5–6a–c, 7a–d and 8–11a–c was carried out by the Beirut reaction (Scheme 1). The appropriate benzofuroxans 4a–d (2.4 mmol) were obtained by previously described methods [50] and appropriate trifluoromethyl-substituted 1,3-dicarbonyl compounds (9.6 mmol) were dissolved in the mixture of dry chloroform (10 mL) and triethylamine (1 mL). When the reaction was finished, the solvent was evaporated and resulted yellow solid or brown oil was precipitated from dichloromethane-hexane mixture (1:3). The products were purified by flash chromatography on a silica gel using eluting solvent (toluene-ethyl acetate mixture, 5:1).

3.1.3. 2-Acetyl-7-fluoro-3-trifluoromethylquinoxaline 1,4-Dioxide (6a)

This compound was obtained in 72% yield from benzofuroxane 4a and 1,1-trifluoropentane-2,4-dione following the general procedure, mp 153–155 °C. 1H-NMR (400 MHz, DMSO-d6) δ 8.60 (1H, dd, J1 = 9.9, J2 = 4.8, H-8); 8.24 (1H, br. d, J = 7.8, H-5); 8.01 (1H, td, J1 = 7.8, J2 = 2.5, H-6); 2.92 (2H, q, J = 7.2, CH2CH3); 1.16 (3H, s, CH3). 13C-NMR (100 MHz, DMSO-d6) δ 194.9 (CO) 138.4 (9-C); 138.4 (2-C); 138.3 (10-C); 134.2 (6-CH); 133.4 (7-CH); 128.2 (q, J = 256.9, 7-CF); 139.8 (d, J = 11.5, 9-C); 139.2 (2-C); 135.8 (10-C); 127.7 (q, J = 33.7, 3-C); 123.7 (d, J = 9.9, 5-CH); 122.9 (d, J = 26.1, 6-CH); 119.1 (q, J = 272.9, CF3); 105.3 (d, J = 28.4, 8-CH). HRMS (ESI) calculated for C11H7F4N2O3+ [M+H]+ 291.0387, found 291.0414.

3.1.4. 7-Fluoro-2-propionyl-3-trifluoromethylquinoxaline 1,4-Dioxide (6d)

This compound was obtained in 83% yield from benzofuroxane 4d and 1,1,1-trifluorohexane-2,4-dione following the general procedure, mp 159–160 °C. 1H-NMR (400 MHz, DMSO-d6) δ 8.60 (1H, dd, J1 = 9.9, J2 = 4.8, H-8); 8.24 (1H, br. d, J = 7.8, H-5); 8.01 (1H, td, J1 = 7.8, J2 = 2.5, H-6); 2.92 (2H, q, J = 7.2, CH2CH3); 1.16 (3H, s, CH3). 13C-NMR (100 MHz, DMSO-d6) δ 194.6 (CO) 164.8 (d, J = 256.3, 7-CF); 139.8 (d, J = 12.2, 9-C); 139.1 (2-C); 135.9 (10-C); 127.9 (q, J = 36.6, 3-C); 123.7 (d, J = 9.9, 5-CH); 122.8 (d, J = 25.9, 6-CH); 119.1 (d, J = 273.9, CF3); 105.3 (d, J = 28.2, 8-CH). HRMS (ESI) calculated for C12H6F3N3O4+ [M+H]+ 305.0544, found 305.0507.

3.1.5. 2-Propionyl-3-trifluoromethylquinoxaline 1,4-Dioxide (7d)

This compound was obtained in 59% yield from benzofuroxane 4d and 1,1,1-trifluorohexane-2,4-dione following the general procedure, mp 178–179 °C (139–140 °C, [23]). 1H-NMR (400 MHz, DMSO-d6) δ 8.52 (1H, dd, J1 = 8.2, J2 = 1.6, H-8); 8.46 (1H, dd, J1 = 8.2, J2 = 1.6, H-5); 8.12 (1H, td, J1 = 7.0, J2 = 1.6, H-7); 8.08 (1H, td, J1 = 7.0, J2 = 1.6, H-6); 2.92 (2H, q, J = 7.0, CH3CH2CO); 1.16 (3H, s, J = 7.0, CH3CH2CO). 13C-NMR (100 MHz, DMSO-d6) δ 194.9 (CO) 138.4 (9-C); 138.4 (2-C); 138.3 (10-C); 134.2 (6-CH); 133.4 (7-CH); 128.2 (q, J = 32.0, 3-C); 120.1 (8-CH); 119.7 (5-CH); 119.2 (q, J = 273.8, CF3); 35.2 (CH3CH2CO); 7.1 (CH3CH2CO).

3.1.6. 2-Ethoxycarbonyl-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (12a)

To a solution of 3-carboethoxy-7-fluoro-3-trifluoromethylquinoxaline 1,4-dioxide 5a (150 mg, 0.47 mmol) in tetrahydrofuran (10 mL) N-Boc-piperazine (260 mg, 1.4 mmol) and triethylamine (100 µL) were added and the mixture was stirred at room temperature equipped with a GraseSmart RP-18, 6 × 250 mm column (Eka Chemicals AB, Bohus, Sweden). Eluents: A, H3PO4 (0.01 M); B, MeCN. All solutions were evaporated at reduced pressure on a Büchi-R200 rotary evaporator at a temperature below 50 °C. All products were dried under vacuum at room temperature. Unless specified otherwise all solvents, chemicals, and reagents were obtained from Sigma-Aldrich (3050 Spruce Street, St. Louis, USA) and used without purification. The purity of compounds 12–18 was >95% as determined by HPLC analysis. All products were dried under vacuum at room temperature. The corresponding benzofuroxans 4a–d were prepared as described [50].
for 5 h. After the reaction was completed (determined by TLC), the reaction mixture was evaporated, the residue was purified by column chromatography on a silica gel in chloroform-acetone (10:1). The residue was crystallized from dichloromethane-n-hexane mixture. Obtained Boc-12a was dissolved in tetrahydrofuran (3 mL) and the 3M solution of HCl in diethyl ether (2 mL) was added. The reaction mixture was stirred at room temperature for 3 h and evaporated. The crystals were dissolved in water (1 mL), filtered, the product was precipitated with methanol-ether mixture (1:3). The formed precipitate was collected by filtration, washed with mixture of methanol-diethyl ether (1:5), n-hexane and dried. The yield of hydrochloride of 12a was 84 mg (46%) as an orange powder, mp 200–202 °C (dec.). HPLC (LW = 335 nm, gradient B 20/80% (45 min)) tR = 12.9 min, purity 98.3%. λmax, EtOH: 272, 302, 337, 382 nm. 1H-NMR (400 MHz, DMSO-d6) δ 9.64 (2H, br. s, NH2+); 8.27 (1H, d, J = 9.0, H-5); 7.64 (1H, d, J = 9.0, H-6); 7.48 (1H, s, H-8); 4.45 (2H, q, J = 7.0, OCH2CH3); 3.82 (4H, m, CH2); 3.27 (4H, m, CH2); 3.13 (3H, t, J = 7.0, OCH2CH3).

13C-NMR (100 MHz, DMSO-d6) δ 158.1 (CO); 152.9 (7-C); 139.6 (9-C); 133.6 (3-C); 131.5 (10-C); 124.3 (q, J = 33.6, 3-C); 122.7 (6-CH); 121.4 (5-CH); 119.3 (q, J = 272.4, CF3); 97.8 (8-CH); 63.5 (OCH2CH3); 43.6 (2 × CH2); 42.7 (2 × CH2); 13.6 (OCH2CH3). HRMS (ESI) calculated for C16H18F3N4O4+ [M+H]+ 387.1275, found 387.1250.

3.1.7. 2-Ethoxycarbonyl-6-fluoro-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (12b)

This compound was prepared from 5b and N-Boc-piperazine as described for 12a. A yellow powder, yield 42%, mp 208–209 °C (dec.). HPLC (LW = 340 nm, gradient B 20/80% (45 min)) tR = 11.3 min, purity 96.5%. λmax, EtOH: 213, 272, 342, 382 nm. 1H-NMR (400 MHz, DMSO-d6) δ 9.69 (2H, s, NH2+); 8.24 (1H, d, J = 12.9, H-5); 7.73 (1H, d, J = 8.2, H-8); 4.47 (2H, q, J = 7.0, OCH2CH3); 3.62 (2H, br. m, CH2); 3.29 (br. m, 4H, CH2); 1.32 (3H, t, J = 7.0, OCH2CH3). 13C-NMR (100 MHz, DMSO-d6) δ 157.9 (CO) 157.9 (d, J = 10.7, OCH2CH3); 118.9 (q, J = 273.8, CF3); 107.0 (d, J = 29.1, 8-CH); 105.9 (5-CH); 67.3 (OCH2CH3); 46.3 (2 × CH2); 42.3 (2 × CH2); 13.7 (OCH2CH3). HRMS (ESI) calculated for C16H18F3N4O4+ [M+H]+ 405.1180, found 405.1233.

3.1.8. 2-Ethoxycarbonyl-6-chloro-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (12c)

This compound was prepared from 5c and N-Boc-piperazine as described for 12a. A yellow powder, yield 83%, mp 253–254 °C (dec.). HPLC (LW = 280 nm, gradient B 20/80% (455 min)) tR = 13.9 min, purity 96.6%. λmax, EtOH: 235, 267, 282, 345, 393 nm. 1H-NMR (400 MHz, DMSO-d6) δ 8.97 (2H, br. s, NH2+); 8.50 (1H, s, H-8); 7.86 (1H, s, H-5); 4.47 (2H, q, J = 7.0, OCH2CH3); 4.31 (4H, br. m, CH2); 3.46 (4H, br. m, CH2); 1.32 (3H, t, J = 7.0, OCH2CH3).

13C-NMR (100 MHz, DMSO-d6) δ 157.8 (CO); 152.8 (7-C); 138.0 (9-C); 134.6 (3-C); 134.4 (10-C); 133.8 (6-CCl); 127.3 (d, J = 33.7, 3-C); 121.9 (5-CH); 118.9 (q, J = 272.9, CF3); 108.6 (8-CH); 63.8 (OCH2CH3); 47.6 (2 × CH2); 42.9 (2 × CH2); 13.7 (OCH2CH3). HRMS (ESI) calculated for C16H17ClF3N4O4+ [M+H]+ 421.0855, found 421.0883.

3.1.9. 2-Acetyl-7-(piperazin-1-yl)-3-trifluoromethylquinoloxaline 1,4-Dioxide Hydrochloride (13a)

This compound was prepared from 6a and N-Boc-piperazine as described for 12a. A yellow powder, yield 81%, mp 260–261 °C (dec.). HPLC (LW = 336 nm, gradient B 10/90% (45 min)) tR = 12.3 min, purity 94.6%. λmax, EtOH: 216, 271, 301, 336, 381 nm. 1H-NMR (400 MHz, DMSO-d6) δ 9.73 (2H, br. s, NH2+); 8.30 (1H, d, J = 9.6, H-5); 7.86 (1H, d, J = 9.6, H-6); 7.51 (1H, s, H-8); 3.83 (4H, br. m, CH2); 3.24 (4H, br. m, CH2); 2.58 (3H, s, CH3). 13C-NMR (100 MHz, DMSO-d6) δ 191.9 (CO); 152.9 (7-C); 139.6 (9-C); 138.8 (10-C); 131.4 (d, J = 9.2, 2-C); 124.2 (d, J = 33.7, 3-C); 122.5 (5-CH); 121.4 (6-CH); 119.5 (q, J = 272.9, CF3); 97.6 (8-CH); 43.7 (2 × CH2); 42.1 (2 × CH2); 29.3 (CH3). HRMS (ESI) calculated for C15H16F3N4O3+ [M+H]+ 357.1169, found 357.1197.
3.1.10. 2-Acetyl-6-fluoro-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (13b)

This compound was prepared from 6b and N-Boc-piperazine as described for 12a. A yellow powder, yield 63%, mp 255–257 °C (dec.). HPLC (MW = 335 nm, gradient B 20/80% (45 min)) tR = 9.6 min, purity 96.0%. λmax, EtOH: 216, 274, 334, 381, 423 nm. 1H-NMR (400 MHz, DMSO-d6) δ 9.79 (2H, s, NH2); 8.04 (1H, d, J = 12.9, H-5); 7.74 (1H, d, J = 7.8, H-8); 3.65 (4H, br. m, CH2); 3.29 (4H, br. m, CH2); 2.59 (3H, s, CH3). 13C-NMR (100 MHz, DMSO-d6) δ 191.1 (CO); 157.5 (d, J = 259.2, 6-CH); 145.4 (d, J = 10.7, 6-C); 138.5 (9-C); 136.2 (2-C); 133.5 (d, J = 11.5, 10-C); 126.4 (d, J = 34.5, 3-C); 119.1 (q, J = 273.8, CF3); 106.8 (d, J = 29.1, 5-CH); 105.7 (8-CH); 46.3 (2 × CH2); 42.2 (2 × CH2); 29.3 (CH3). HRMS (ESI) calculated for C15H15F4N4O5+[M+H]+ 375.1075, found 375.1167.

3.1.11. 2-Acetyl-7-chloro-6-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (13c)

This compound was prepared from 6c and N-Boc-piperazine as described for 12a. A yellow powder, yield 78%, mp > 260 °C (dec.). HPLC (MW = 340 nm, gradient B 10/90% (45 min)) tR = 14.0 min, purity 79.4%. λmax, EtOH: 222, 244, 342, 391 nm. 1H-NMR (400 MHz, DMSO-d6) δ 9.82 (2H, br. s, NH2); 8.52 (1H, s, H-5); 7.86 (1H, s, H-8); 3.53–3.51 (4H, m, CH2); 3.31–3.30 (4H, m, CH2); 2.60 (3H, s, CH3). 13C-NMR (100 MHz, DMSO-d6) δ 191.4 (CO); 152.8 (7-C); 138.9 (9-C); 134.2 (6-CCl); 131.4 (2-C); 121.7 (5-CH); 119.1 (q, J = 273.7, CF3); 108.2 (8-CH); 47.4 (2 × CH2); 42.5 (2 × CH2); 29.2 (CH3). HRMS (ESI) calculated for C15H15ClF3N4O5+[M+H]+ 391.0779, found 391.0797.

3.1.12. 7-(Piperazin-1-yl)-2-propionyl-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (14a)

This compound was prepared from 7a and N-Boc-piperazine as described for 12a. A yellow powder, yield 76%, mp 180–182 °C (dec.). HPLC (MW = 300 nm, gradient B 20/80% (45 min)) tR = 16.2 min, purity 95.5%. λmax, EtOH: 272, 302, 337, 371, 382 nm. 1H-NMR (400 MHz, DMSO-d6) δ 8.99 (2H, br. s, NH2); 8.31 (1H, d, J = 8.0, H-5); 7.86 (1H, d, J = 8.0, H-6); 7.52 (1H, s, H-8); 3.79 (4H, br. m, CH2); 3.45 (4H, br. m, CH2); 2.90 (2H, br. m, COCH2CH3); 1.14 (3H, br. m, COCH2CH3). 13C-NMR (100 MHz, DMSO-d6) δ 195.2 (CO); 152.9 (7-C); 139.6 (9-C); 138.7 (2-C); 131.4 (10-C); 124.4 (d, J = 33.6, 3-C); 122.6 (6-CH); 121.4 (5-CH); 119.5 (q, J = 272.4, CF3); 97.6 (8-CH); 43.8 (2 × CH2); 42.4 (2 × CH2); 35.1 (CH2CH3); 7.2 (CH2CH3). HRMS (ESI) calculated for C11H14F2N3O5+[M+H]+ 371.1326, found 371.1338.

3.1.13. 6-Fluoro-7-(piperazin-1-yl)-2-propionyl-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (14b)

This compound was prepared from 7b and N-Boc-piperazine as described for 12a. A yellow powder, yield 58%, mp > 260 °C (dec.). HPLC (MW = 335 nm, gradient B 10/90% (45 min)) tR = 14.5 min, purity 95.4%. λmax, EtOH: 216, 274, 335, 388 nm. 1H-NMR (400 MHz, DMSO-d6) δ 9.77 (2H, br. s, NH2); 8.24 (1H, d, J = 12.9, H-5); 7.74 (1H, d, J = 8.2, H-8); 3.64 (4H, br. m, CH2); 3.37–3.35 (4H, m, CH2); 2.90 (2H, q, J = 7.3, COCH2CH3); 1.14 (3H, t, J = 7.3, COCH2CH3). 13C-NMR (100 MHz, DMSO-d6) δ 194.7 (CO); 157.5 (d, J = 259.2, 6-CH); 144.8 (d, J = 11.5, 7-C); 138.4 (9-C); 136.2 (2-C); 133.5 (d, J = 34.5, 10-C); 126.5 (d, J = 34.5, 3-C); 118.3 (q, J = 273.8, CF3); 106.8 (d, J = 29.1, 5-CH); 105.6 (8-CH); 46.2 (2 × CH2); 42.2 (2 × CH2); 35.1 (CH2CH3); 7.1 (CH2CH3). HRMS (ESI) calculated for C16H16F4N4O5+[M+H]+ 389.1231, found 389.1221.

3.1.14. 6-Chloro-7-(piperazin-1-yl)-2-propionyl-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (14c)

This compound was prepared from 7c and N-Boc-piperazine as described for 12a. A yellow powder, yield 45%, mp 257–258 °C (dec.). HPLC (MW = 300 nm, gradient B 20/80% (45 min)) tR = 15.8 min, purity 97.3%. λmax, EtOH: 223, 244, 342, 392 nm. 1H-NMR (400 MHz, DMSO-d6) δ 9.03 (2H, br. s, NH2); 8.51 (1H, s, H-8); 7.85 (1H, s, H-5); 3.47 (4H,
br. m, CH$_2$); 3.35 (4H, br. m, CH$_2$); 2.90 (2H, q, $J$ = 6.8, COCH$_2$CH$_3$); 1.13 (3H, t, $J$ = 6.8, COCH$_3$CH$_3$).$^{13}$C-NMR (100 MHz, DMSO-$d_6$) δ 194.8 (CO); 152.8 (7-C); 138.9 (9-C); 138.0 (2-C); 134.3 (10-C); 134.3 (6-CHCl); 127.3 (d, $J$ = 34.3, 3-C); 121.6 (5-CH); 119.2 (q, $J$ = 273.2, CF$_3$); 108.4 (8-CH); 47.6 (2 × CH$_2$); 42.9 (2 × CH$_2$); 30.7 (CH$_2$CH$_3$); 7.2 (CH$_2$CH$_3$). HRMS (ESI) calculated for C$_{18}$H$_{17}$ClF$_3$N$_3$O$_3$+$^{+}$ [M+H]$^+$ = 405.0936, found 405.0947.

3.1.15. 2-Benzoyl-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (15a)

This compound was prepared from 8a and N-Boc-piperazine as described for 12a. An orange powder, yield 74%, mp 234–236 °C (dec.). HPLC (LW = 340 nm, gradient B 10/90% (45 min)) $t_R$ = 8.79 min, purity 97.7%. $\lambda_{max}$, EtOH: 206, 275, 340, 383 nm. $^1$H-NMR (400 MHz, DMSO-$d_6$) δ 9.65 (2H, br. s, NH$_2^+$); 8.38 (1H, d, $J$ = 9.8, H-5); 8.09 (2H, d, $J$ = 7.8, C$_6$H$_3$); 7.89 (1H, d, $J$ = 9.8, H-6); 7.75 (1H, t, $J$ = 7.8, C$_6$H$_3$); 7.58 (2H, t, $J$ = 7.8, C$_6$H$_3$); 7.49 (1H, s, H-8); 3.82 (4H, br. m, CH$_2$); 3.25 (4H, br. m, CH$_2$). $^{13}$C-NMR (100 MHz, DMSO-$d_6$) δ 184.6 (CO); 152.9 (7-C); 139.7 (9-C); 137.4 (1′-C); 135.2 (4′-CH); 134.1 (2-C); 132.0 (10-C); 129.3 (2 × 2′-CH); 129.2 (2 × 3′-CH); 124.7 (d, $J$ = 46.7, 3-C); 122.6 (6-CH); 121.5 (5-CH); 119.5 (q, $J$ = 272.9, CF$_3$); 43.7 (2 × CH$_2$); 42.1 (2 × CH$_2$). HRMS (ESI) calculated for C$_{23}$H$_{17}$F$_3$N$_3$O$_3$+$^+$ [M+H]$^+$ = 419.1326, found 419.1327.

3.1.16. 2-Benzoyl-6-fluoro-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (15b)

This compound was prepared from 8b and N-Boc-piperazine as described for 12a. $R_f$ = 0.47 (chloroform-acetone, 5:1). A yellow powder, yield 52%, mp 215–216 °C (dec.). HPLC (LW = 270 nm, gradient B 20/80% (45 min)) $t_R$ = 14.7 min, purity 95.1%. $\lambda_{max}$, EtOH: 271, 338, 391 nm. $^1$H-NMR (400 MHz, DMSO-$d_6$) δ 9.71 (2H, br. s, NH$_2^+$); 8.32 (1H, d, $J$ = 12.5, H-5); 8.10 (2H, d, $J$ = 8.2, C$_6$H$_3$); 7.76 (1H, t, $J$ = 7.4, C$_6$H$_3$); 7.71 (1H, d, $J$ = 8.2, H-8); 7.59 (2H, t, $J$ = 7.4, C$_6$H$_3$); 3.62 (4H, br. m, CH$_2$); 3.29 (4H, br. m, CH$_2$). $^{13}$C-NMR (100 MHz, DMSO-$d_6$) δ 184.6 (CO); 152.9 (7-C); 139.7 (9-C); 137.4 (1′-C); 135.2 (4′-CH); 134.1 (2-C); 132.0 (10-C); 129.3 (2 × 2′-CH); 129.2 (2 × 3′-CH); 124.7 (d, $J$ = 46.7, 3-C); 122.6 (6-CH); 121.5 (5-CH); 119.5 (q, $J$ = 272.9, CF$_3$); 43.7 (2 × CH$_2$); 42.1 (2 × CH$_2$). HRMS (ESI) calculated for C$_{23}$H$_{18}$F$_2$N$_3$O$_3$+$^+$ [M+H]$^+$ = 437.1231, found 437.1253.

3.1.17. 2-Benzoyl-6-chloro-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (15c)

This compound was prepared from 8c and N-Boc-piperazine as described for 12a. A yellow powder, yield 84%, mp 243–244 °C (dec.). HPLC (LW = 345 nm, gradient B 10/90% (45 min)) $t_R$ = 17.5 min, purity 96.7%. $\lambda_{max}$, EtOH: 258, 284, 345, 394 nm. $^1$H-NMR (400 MHz, DMSO-$d_6$) δ 9.88 (2H, br. s, NH$_2^+$); 8.57 (1H, s, H-8); 8.10 (2H, d, $J$ = 7.8, C$_6$H$_3$); 7.82 (1H, s, H-5); 7.74 (1H, m, C$_6$H$_3$); 7.59 (2H, t, $J$ = 7.8, C$_6$H$_3$); 3.51 (4H, br. m, CH$_2$); 3.29 (4H, br. m, CH$_2$). $^{13}$C-NMR (100 MHz, DMSO-$d_6$) δ 184.2 (CO); 152.7 (7-C); 139.9 (9-C); 138.3 (10-C); 137.7 (1′-C); 135.4 (4′-CH); 134.9 (6-CHCl); 134.0 (d, $J$ = 24.5, 3-C); 131.8 (2-C); 129.3 (2 × 2′-CH); 129.2 (2 × 3′-CH); 121.9 (5-CH); 108.3 (CH); 119.1 (q, $J$ = 274.5, CF$_3$); 47.4 (2 × CH$_2$); 42.6 (2 × CH$_2$). HRMS (ESI) calculated for C$_{23}$H$_{17}$ClF$_3$N$_3$O$_3$+$^+$ [M+H]$^+$ = 453.0936, found 453.0918.

3.1.18. 2-Benzoyl-6,7-di(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (15d)

This compound was isolated as a minor component in the synthesis of the derivative 15b described in 3.1.16. $R_f$ = 0.29 (chloroform-acetone, 5:1). An orange powder, yield 20%, mp >260 °C (dec.). HPLC (LW = 335 nm, gradient B 10/90% (45 min)) $t_R$ = 12.80 min, purity 97.9%. $\lambda_{max}$, EtOH: 258, 284, 345 nm. $^1$H-NMR (400 MHz, DMSO-$d_6$) δ 7.99 (2H, d, $J$ = 7.8, C$_6$H$_3$); 7.81 (1H, s, H-8); 7.73 (2H, t, $J$ = 7.8, C$_6$H$_3$); 7.66 (1H, s, H-5); 7.56 (1H, t, $J$ = 7.8, C$_6$H$_3$); 3.52 (8H, br. m, CH$_2$); 3.35 (8H, br. m, CH$_2$). $^{13}$C-NMR (100 MHz, DMSO-$d_6$) δ 185.1 (CO) 150.6 (7-C); 149.8 (6-C); 144.9 (9-C); 136.9 (2-C); 136.0 (1′-C); 135.7 (4′-CH); 134.5 (10-C);
3.1.19. 2-(Furan-2-carbonyl)-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (16a)

This compound was prepared from 9a and N-Boc-piperazine as described for 12a. An orange powder, yield 71%, mp 220–221 °C (dec.). HPLC (ILW = 340 nm, gradient B 10/90% (45 min)) tR = 11.0 min, purity 97.9%. H-NMR (400 MHz, DMSO- d6) δ 9.60 (2H, br. s, NH2); 8.37 (1H, d, J = 8.9, H-5); 8.20 (1H, br. m, C6H2O); 7.89 (1H, d, J = 8.9, H-6); 7.85 (1H, br. m, C6H2O); 7.50 (1H, s, H-8); 6.82 (1H, br. m, C6H2O); 3.81 (4H, br. m, CH2); 3.24 (4H, m, CH2). 13C-NMR (100 MHz, DMSO- d6) δ 170.5 (CO); 152.9 (7-C); 150.6 (C9H2O); 140.0 (9-C); 136.3 (2-C); 131.9 (10-C); 125.4 (d, J = 32.9, 3-C); 123.6 (C6H2O); 122.7 (6-CH); 121.5 (5-CH); 119.5 (d, J = 273.8, CF3); 113.6 (C6H2O); 97.9 (8-CH); 43.7 (2 × CH2); 42.1 (2 × CH2). HRMS (ESI) calculated for C18H16F3N4O4+ [M+H]+ 409.1118, found 409.1078.

3.1.20. 6-Fluoro-2-(furan-2-carbonyl)-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (16b)

This compound was prepared from 9b and N-Boc-piperazine as described for 12a. Rf = 0.52 (chloroform-acetone, 5:1). A yellow powder, yield 47%, mp 246–248 °C (dec.). HPLC (ILW = 300 nm, gradient B 20/80% (45 min)) tR = 12.0 min, purity 95.5%. λmax, EtOH: 216, 276, 293, 338, 387, 418 nm. H-NMR (400 MHz, DMSO- d6) δ 9.58 (2H, br. s, NH2); 8.33 (1H, d, J = 12.9, H-5); 8.23 (1H, br. m, C6H2O); 7.86 (1H, br. m, C6H2O); 7.73 (1H, d, J = 8.2, H-8); 6.83–6.82 (1H, m, C6H2O); 3.61 (4H, br. m, CH2); 3.29 (4H, m, CH2). 13C-NMR (100 MHz, DMSO- d6) δ 170.1 (CO) 157.7 (d, J = 260.7, 6-CF); 150.9 (C6H2O); 150.1 (C6H2O); 144.9 (d, J = 11.5, 7-C); 136.7 (2-C); 136.1 (d, J = 4.6, 9-C); 134.3 (d, J = 12.3, 10-C); 130.1 (d, J = 29.1, 3-C); 124.1 (C6H2O); 119.1 (d, J = 241.5, CF3); 113.6 (C6H2O); 107.1 (d, J = 30.5, 5-CH); 106.1 (d, J = 4.6, 8-CH); 46.4 (2 × CH2); 42.3 (2 × CH2). HRMS (ESI) calculated for C18H15F4N3O4+ [M+H]+ 427.1024, found 427.1030.

3.1.21. 6-Chloro-2-(furan-2-carbonyl)-7-(piperazin-1-yl)-3-trifluoromethylquinoxaline 1,4-Dioxide Hydrochloride (16c)

This compound was prepared from 9c and N-Boc-piperazine as described for 12a. A yellow powder, yield 82%, mp > 260 °C (dec.). HPLC (ILW = 300 nm, gradient B 10/90% (45 min)) tR = 13.0 min, purity 96.4%. λmax, EtOH: 291, 374, 499 nm. H-NMR (400 MHz, DMSO- d6) δ 8.53 (1H, s, H-5); 8.14 (1H, br. m, C6H2O); 7.83 (1H, s, H-8); 7.76 (1H, br. m, C6H2O); 6.80–6.79 (1H, m, C6H2O); 3.45 (4H, br. m, CH2); 3.31 (4H, m, CH2). 13C-NMR (100 MHz, DMSO- d6) δ 170.4 (CO); 153.5 (7-C); 151.5 (C6H2O); 150.4 (C6H2O); 138.8 (9-C); 136.9 (10-C); 135.5 (d, J = 3.8, 2-C); 135.4 (6-CHCl); 128.4 (q, J = 32.9, 3-C); 124.8 (C6H2O); 122.2 (5-CH); 121.1 (q, J = 265.1, CF3); 114.2 (C6H2O); 92.3 (8-CH); 47.7 (2 × CH2); 43.1 (2 × CH2). HRMS (ESI) calculated for C18H15ClF3N3O4+ [M+H]+ 443.0728, found 443.0734.

3.1.22. 6,7-Di(piperazin-1-yl)-2-(furan-2-carbonyl)-3-trifluoromethylquinoxaline 1,4-Dioxide Dihydrochloride (16d)

This compound was isolated as a minor component in the synthesis of the derivative 16b described in 3.1.20. Rf = 0.36 (chloroform-acetone, 5:1). An orange powder, yield 25%, mp > 260 °C (dec.). HPLC (ILW = 335 nm, gradient B 10/90% (45 min)) tR = 8.55 min, purity 98.0%. λmax, EtOH: 209, 247, 274, 332, 442 nm. H-NMR (400 MHz, DMSO- d6) δ 8.66 (4H, br. s, NH2); 8.20–8.17 (1H, br. m, C6H2O); 7.80–7.79 (1H, m, C6H2O); 7.63 (1H, s, H-8); 7.48 (1H, s, H-5); 6.81–6.79 (1H, br. m, C6H2O); 3.98–3.92 (4H, br. m, CH2); 3.53–3.51 (4H, br. m, CH2); 3.36–3.26 (8H, m, CH2). 13C-NMR (100 MHz, DMSO- d6) δ 170.8 (CO) 150.5 (C6H2O); 148.3 (7-C); 148.2 (9-C); 147.3 (6-C); 147.3 (2-C); 134.4 (10-C); 133.9 (C6H2O); 125.9 (d, J = 32.2, 2-C); 123.5 (C6H2O); 119.6 (d, J = 273.8, CF3); 113.6 (C6H2O); 103.4 (8-CH);
102.2 (5-CH); 53.3 (2 × CH$_2$); 48.8 (4 × CH$_2$); 48.6 (4 × CH$_2$). HRMS (ESI) calculated for C$_{22}$H$_{23}$F$_3$N$_2$O$_7$ [M+H]$^+$ 493.1806, found 493.1803.

3.1.23. 7-(Piperazin-1-yl)-2-(thiophene-2-carbonyl)-3-trifluoromethylquinoline 1,4-Dioxide Hydrochloride (17a)

This compound was prepared from 10a and N-Boc-piperazine as described for 12a. An orange powder, yield 87%, mp 210–212 °C (dec.). HPLC (LW = 470 nm, gradient B 20/60/70% (43 min)) t$_R$ = 16.72 min, purity 94.9%. $\lambda_{	ext{max}}$, EtOH: 235, 274, 301, 339, 383, 462 nm; $^{1}$H-NMR (400 MHz, DMSO-$d_6$) $\delta$ 9.65 (2H, br. s, NH$_2^+$); 8.38 (1H, d, $J$ = 9.4, H-5); 8.25 (1H, d, $J$ = 5.1, C$_4$H$_3$S); 8.18 (1H, d, $J$ = 4.3, C$_4$H$_3$S); 7.89 (1H, d, $J$ = 9.4, H-6); 7.51 (1H, s, H-8); 7.28 (1H, t, $J$ = 4.3, C$_4$H$_3$S); 3.81 (4H, br. s, CH$_2$); 3.24 (4H, br. s, CH$_2$). $^{13}$C-NMR (100 MHz, DMSO-$d_6$) $\delta$ 176.51 (CO) 152.91 (7-C); 140.97 (9-C); 140.07 (2-C); 138.05 (2′-CH); 137.98 (1′-C); 137.73 (4′-CH); 136.88 (10-C); 132.00 (3-C); 129.38 (3′-CH); 122.38 (6-CH); 121.9 (q, $J$ = 274.5, CF$_3$); 121.47 (5-CH); 43.64 (2 × CH$_2$); 42.06 (2 × CH$_2$). HRMS (ESI) calculated for C$_{18}$H$_{16}$F$_3$N$_2$O$_7$ [M+H]$^+$ 425.0890, found 425.0890.

3.1.24. 6-Fluoro-7-(piperazin-1-yl)-2-(thiophene-2-carbonyl)-3-trifluoromethylquinoline 1,4-Dioxide Hydrochloride (17b)

This compound was prepared from 10b and N-Boc-piperazine as described for 12a. $R_S$ = 0.54 (chloroform-acetone, 5:1). A yellow powder, yield 59%, mp 226–228 °C (dec.). HPLC (LW = 330 nm, gradient B 20/60/70% (43 min)) t$_R$ = 12.32 min, purity 94.4%. $\lambda_{\text{max}}$, EtOH: 241, 337, 444 nm; $^{1}$H-NMR (400 MHz, DMSO-$d_6$) $\delta$ 9.71 (2H, br. s, NH$_2^+$); 8.32 (1H, d, $J$ = 12.9, H-5); 8.28 (1H, d, $J$ = 4.0, C$_4$H$_3$S); 8.18 (1H, d, $J$ = 4.0, C$_4$H$_3$S); 7.73 (1H, d, $J$ = 8.2, H-8); 7.29 (1H, t, $J$ = 4.0, C$_4$H$_3$S); 3.62 (4H, br. m, CH$_2$); 3.39 (4H, br. m, CH$_2$). $^{13}$C-NMR (100 MHz, DMSO-$d_6$) $\delta$ 176.6 (CO) 158.1 (d, $J$ = 259.2, 6-CH); 145.3 (d, $J$ = 10.7, 7-C); 142.3 (9-C); 138.8 (2-C); 138.7 (1′-C); 138.4 (2′-CH); 137.2 (4′-CH); 134.7 (d, $J$ = 10.7, 10-C); 129.9 (3′-CH); 127.9 (q, $J$ = 33.7, 3-C); 119.6 (q, $J$ = 272.2, CF$_3$); 107.4 (d, $J$ = 28.4, 5-CH); 106.5 (8-CH); 46.7 (2 × CH$_2$); 42.7 (2 × CH$_2$). HRMS (ESI) calculated for C$_{18}$H$_{16}$F$_3$N$_2$O$_7$ [M+H]$^+$ 443.0796, found 443.0774.

3.1.25. 6-Chloro-7-(piperazin-1-yl)-2-(thiophene-2-carbonyl)-3-trifluoromethylquinoline 1,4-Dioxide Hydrochloride (17c)

This compound was prepared from 10c and N-Boc-piperazine as described for 12a. A yellow powder, yield 73%, mp 235–236 °C (dec.). HPLC (LW = 395 nm, gradient B 20/60/70% (45 min)) t$_R$ = 19.84 min, purity 97.7%. $\lambda_{\text{max}}$, EtOH: 243, 287, 345, 394 nm; $^{1}$H-NMR (400 MHz, DMSO-$d_6$) $\delta$ 9.59 (2H, br. s, NH$_2^+$); 8.59 (1H, s, H-8); 8.29 (1H, d, $J$ = 7.4, C$_4$H$_3$S); 8.20 (1H, d, $J$ = 4.0, C$_4$H$_3$S); 7.85 (1H, s, H-5); 7.30 (1H, t, $J$ = 4.0, C$_4$H$_3$S); 4.33 (4H, br. m, CH$_2$); 3.31 (4H, br. m, CH$_2$). $^{13}$C-NMR (100 MHz, DMSO-$d_6$) $\delta$ 176.0 (CO) 152.7 (7-C); 140.8 (9-C); 138.4 (2-C); 138.5 (2′-CH); 138.1 (4′-CH); 137.1 (1′-C); 134.9 (10-C); 134.1 (6-CH); 129.5 (3′-CH); 128.1 (q, $J$ = 32.9, 3-C); 121.9 (5-CH); 117.8 (q, $J$ = 273.8, CF$_3$); 47.5 (2 × CH$_2$); 42.6 (2 × CH$_2$). HRMS (ESI) calculated for C$_{18}$H$_{16}$ClF$_3$N$_2$O$_7$ [M+H]$^+$ 459.0500, found 459.0511.

3.1.26. 6,7-(Dipiperazin-1-yl)-2-(thiophene-2-carbonyl)-3-trifluoromethylquinoline 1,4-Dioxide Hydrochloride (17d)

This compound was isolated as a minor component in the synthesis of the derivative 17b described in 3.1.24. $R_S$ = 0.32 (chloroform-acetone, 5:1). An orange powder, yield 26%, mp 251–252 °C (dec.). HPLC (LW = 390 nm, gradient B 20/60/70% (43 min)) t$_R$ = 18.24 min, purity 99.7%. $\lambda_{\text{max}}$, EtOH: 234, 275, 298, 337, 391 nm; $^{1}$H-NMR (400 MHz, DMSO-$d_6$) $\delta$ 9.70 (4H, br. m, 2 × NH$_2^+$); 8.26 (1H, d, $J$ = 4.3, C$_4$H$_3$S); 8.14 (1H, d, $J$ = 4.3, C$_4$H$_3$S); 7.80 (1H, s, H-8); 7.67 (1H, s, H-5); 7.27 (1H, t, $J$ = 4.3, C$_4$H$_3$S); 3.56 (8H, br. m, 4 × CH$_2$); 3.36 (8H, br. m, 4 × CH$_2$). $^{13}$C-NMR (100 MHz, DMSO-$d_6$) $\delta$ 176.8 (CO) 150.1 (7-C); 149.4 (6-C); 141.5 (9-C); 138.6 (2-C); 138.3 (2′-CH); 138.1 (1′-C); 135.7 (4′-CH); 135.6 (10-C); 129.9 (3′-CH); 127.5 (q, $J$ = 32.2, 3-C); 120.1 (q, $J$ = 223.9, CF$_3$); 107.4 (8-CH); 106.8 (5-CH); 46.2 (2 × CH$_2$);
Pharmaceuticals 2022, 15, 155

3.1.27. 2-(1-Naphthoyl)-7-(piperazin-1-yl)-3-trifluoromethylquinoline 1,4-Dioxide Hydrochloride (18a)

This compound was prepared from 11a and N-Boc-piperazine as described for 12a. An orange powder, yield 91%, mp > 260 °C (dec.). HPLC (LW = 470 nm, gradient B 20/60/70% (43 min)) t_R = 23.51 min, purity 97.8%. λ_max, EtOH: 256, 289, 430 nm. 1H-NMR (400 MHz, DMSO-d_6) δ 9.70 (2H, br. s, NH_2^+); 8.81 (1H, s, H-8); 8.41 (1H, d, J = 9.0, H-6); 8.09 (2H, br. m, C_{10}H_2); 7.84–7.92 (2H, m, C_{10}H_2); 7.64 (1H, t, J = 7.0, C_{10}H_2); 7.61 (1H, t, J = 7.0, C_{10}H_2); 7.49 (1H, br. m, C_{10}H_2); 3.81 (4H, br. m, CH_2); 3.39 (4H, br. m, CH_2). 13C-NMR (100 MHz, DMSO-d_6) δ 184.5 (CO) 158.1 (6-CF); 145.4 (7-C); 137.9 (6-C); 137.2 (5′-C); 134.6 (10-C); 133.2 (9′-C); 131.9 (10′-C); 131.6 (4′-CH); 129.7 (2′-CH); 129.6 (8′-CH); 129.2 (5′-CH); 127.9 (3′-CH); 127.4 (7′-CH); 122.9 (6′-CH); 122.6 (6-CH); 125.5 (q, J = 33.7, 3-C); 121.5 (5′-CH); 120.9 (q, J = 273.8, CF_3); 97.8 (8-CH); 43.6 (2 × CH_2); 42.1 (2 × CH_2). HREMS (ESI) calculated for C_{24}H_{19}F_3N_4O_5^+ [M+H]^+ 469.1492, found 469.1492.

3.1.28. 6-Fluoro-2-(1-naphthoyl)-7-(piperazin-1-yl)-3-trifluoromethylquinoline 1,4-Dioxide Hydrochloride (18b)

This compound was prepared from 11b and N-Boc-piperazine as described for 12a. A yellow powder, yield 48%, mp > 260 °C (dec.). R_t = 0.44 (chloroform-acetone, 5:1). HPLC (LW = 393 nm, gradient B 20/60/70% (43 min)) t_R = 26.09 min, purity 100.0%. λ_max, EtOH: 256, 285, 298, 341, 393 nm. 1H-NMR (400 MHz, DMSO-d_6) δ 9.69 (2H, br. s, NH_2^+); 8.83 (1H, s, H-8); 8.38 (1H, d, J = 12.5, H-5); 8.11 (2H, br. m, C_{10}H_2); 8.04 (2H, t, J = 8.6, C_{10}H_2); 7.74–7.72 (2H, m, C_{10}H_2); 7.64 (1H, t, J = 7.0, C_{10}H_2); 3.62 (4H, br. m, CH_2); 3.29 (4H, br. m, CH_2). 13C-NMR (100 MHz, DMSO-d_6) δ 184.6 (CO) 158.1 (d, J = 158.1, 6-CF); 145.4 (7-C); 137.8 (9-C); 137.2 (2-C); 136.4 (1′-C); 134.9 (q, J = 20.7, 3-C); 134.6 (10-C); 133.2 (4′-CH); 132.8 (6′-C); 131.9 (10′-C); 130.2 (2′-CH); 130.1 (8′-CH); 129.7 (5′-CH); 128.4 (3′-CH); 127.9 (7′-CH); 123.4 (6′-CH); 119.8 (q, J = 273.8, CF_3); 107.5 (d, J = 29.1, 5′-CH); 106.4 (8-CH); 46.7 (2 × CH_2); 42.7 (2 × CH_2). HREMS (ESI) calculated for C_{24}H_{19}F_3N_4O_5^+ [M+H]^+ 487.1388, found 487.1414.

3.1.29. 6-Chloro-2-(1-naphthoyl)-7-(piperazin-1-yl)-3 trifluoromethylquinoline 1,4-Dioxide Hydrochloride (18c)

This compound was prepared from 11c and N-Boc-piperazine as described for 12a. A yellow powder, yield 64%, mp > 260 °C (dec.). HPLC (LW = 395 nm, gradient B 20/60/70% (43 min)) t_R = 22.29 min, purity 94.6%. λ_max, EtOH: 256, 287, 298, 348, 395 nm. 1H-NMR (400 MHz, DMSO-d_6) δ 9.70 (2H, br. s, NH_2^+); 8.82 (1H, s, H-8); 8.61 (1H, s, H-5); 8.10 (2H, br. m, C_{10}H_2); 8.05–7.99 (3H, m, C_{10}H_2); 7.72 (1H, t, J = 7.4, C_{10}H_2); 7.62 (1H, t, J = 7.4, C_{10}H_2); 3.49 (4H, br. m, CH_2); 3.28 (4H, br. m, CH_2). 13C-NMR (100 MHz, DMSO-d_6) δ 184.5 (CO) 153.2 (7-C); 149.5 (9-C); 147.4 (2-C); 138.4 (1′-C); 133.9 (10-C); 134.9 (9′-C); 134.2 (10′-C); 132.8 (6-C); 132.3 (4′-CH); 131.9 (q, J = 37.6, 3-C); 131.4 (5′-CH); 129.8 (2′-CH); 129.6 (8′-CH); 129.3 (3′-CH); 127.9 (7′-CH); 127.5 (6′-CH); 122.9 (5′-CH); 120.7 (q, J = 263.0, CF_3); 108.9 (8-CH); 47.9 (2 × CH_2); 43.7 (2 × CH_2). HREMS (ESI) calculated for C_{24}H_{19}ClF_3N_4O_5^+ [M+H]^+ 503.1092, found 503.1071.

3.1.30. 2-(1-Naphthoyl)-7-(dipiperazin-1-yl)-3-trifluoromethylquinoline 1,4-Dioxide Hydrochloride (18d)

This compound was isolated as a minor component in the synthesis of the derivative 18b described in 3.1.28. R_t = 0.25 (chloroform-acetone, 5:1). An orange powder, yield 32%, mp > 260 °C (dec.). HPLC (LW = 440 nm, gradient B 20/60/70% (43 min)) t_R = 19.46 min, purity 98.8%. λ_max, EtOH: 256, 299, 342, 440 nm. 1H-NMR (400 MHz, DMSO-d_6) δ 9.64 (2H, br. s, NH_2^+); 9.59 (2H, br. s, NH_2^+); 8.78 (1H, s, H-8); 8.08 (2H, br. m, C_{10}H_2); 8.02 (2H, t, J = 7.8, C_{10}H_2); 7.84 (1H, s, H-5); 7.71 (1H, t, J = 7.8, C_{10}H_2); 7.65 (1H, br. m, C_{10}H_2); 7.61 (1H, t, J = 7.8, C_{10}H_2); 3.54 (8H, br. m, 4 × CH_2); 3.29 (8H, br. m, 4 × CH_2). 13C-NMR
(100 MHz, DMSO-d$_6$) $\delta$ 184.9 (CO) 150.1 (7'-C); 149.4 (6'-C); 136.6 (9-C); 136.3 (2-C); 135.7 (1'-C); 135.6 (10-C); 133.2 (4'-CH); 132.8 (9'-C); 132.1 (10'-C); 130.2 (2'-CH); 130.1 (8'-CH); 129.6 (5'-CH); 128.4 (3'-CH); 127.9 (q, $J$ = 32.2, 3-C); 127.8 (7'-CH); 123.4 (6'-CH); 119.9 (q, $J$ = 272.9, CF$_3$); 107.5 (5-CH); 106.7 (8-CH); 46.2 (2 $\times$ CH$_2$); 46.0 (2 $\times$ CH$_2$); 42.9 (br. m, 4 $\times$ CH$_2$). HRMS (ESI) calculated for C$_{28}$H$_{28}$F$_3$N$_6$O$_3$ $^+$ [M+H]$^+$ 553.2169, found 553.2147.

3.2. Biology

3.2.1. Microbial Cultures and Growth Conditions

All the bacterial cultures used in this study are summarized in Table 3.

**Table 3. Microbial cultures used in the study.**

| Microbial Strains | Name | Comment | Origin |
|-------------------|------|---------|--------|
|                   | M. smegmatis mc$^2$ 155 | Wild-type (w.t.) strain |        |
|                   | M. smegmatis atR9c | Recombinant strain, mutation: ins C8 (frameshift) in MSMEG,1380. | [42]   |
|                   | M. smegmatis qtfR1-2, qtfR4-7 | Spontaneous M. smegmatis mutants, resistant to the compounds 15b and 16b | This study |
|                   | M. smegmatis 4883c | Recombinant M. smegmatis strain, harboring a deletion of CGCTGCTGC$^{176-184}$ in MSMEG,4883 (ALLP$^{58-61}$ -> V$^{58}$). | This study |
|                   | M. tuberculosis UAlRv | Autoluminescent M. tuberculosis H37Rv strain. | [51]   |
|                   | M. tuberculosis AlRa | Autoluminescent M. tuberculosis H37Ra strain. | [52]   |

The rest of the test strains: Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis ATCC 14990, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, Klebsiella pneumoniae 1951, Pseudomonas aeruginosa ATCC 27853, Candida albicans ATCC 10231, Microsporum canis B-200 were obtained from the culture collection of the Antibiotic Science Center (Moscow, Russian Federation). Strains were stored at $-75$ °C in trypticase soy broth with 15% glycerol. Before the experiment, the bacterial strains were plated on trypticase soy agar, the fungus strains were plated on Sabouraud dextrose agar and incubated at 36 °C.

*Mycobacterium* strains were grown in liquid Middlebrook 7H9 medium (Himedia, Mumbai, India) supplemented with oleic albumin dextrose catalase (OADC, Himedia), 0.1% Tween-80 ($v/v$) and 0.4% glycerol ($v/v$), while the M290 Soyabean Casein Digest Agar (Himedia) and Middlebrook 7H11 agar supplemented with 0.2% glycerol ($v/v$) and OADC were used as solid media for *M. smegmatis* and *M. tuberculosis* growth, respectively. *Escherichia coli* DH5α was used for plasmids propagation and was grown in liquid or on agarized LB medium with the addition of the corresponding selection antibiotics, when required. Cultures in liquid medium were incubated in the Multitron incubator shaker (Infors HT, Bottmingen-Basel, Switzerland) at 37 °C and 250 rpm.

The remaining bacterial and fungi strains were stored at $-75$ °C in trypticase soy broth with 15% glycerol. Before the experiment, the bacterial strains were plated on trypticase soy agar, while the fungi strains were plated on Sabouraud dextrose agar and incubated at 36 °C.

3.2.2. Minimal Inhibitory Concentrations Determination

**MIC Determination on M. smegmatis Strains**

Minimal inhibitory concentrations (MICs) of the studied compounds on *M. smegmatis* were determined in liquid medium by the serial two-fold dilution method, as described
before [53]. Briefly, *M. smegmatis* strains were cultured overnight in 7H9 medium, then diluted in the proportion of 1:200 in fresh medium (to approximately OD_{600} = 0.05), and 196 µL of the diluted culture were poured in sterile non-treated 96-well flat-bottom culture plates (Eppendorf, Hamburg, Germany) and 4 µL of serial two-fold dilutions of the tested compounds in DMSO were added to the wells to final concentrations ranging from 1 to 32 µg/mL (a total of six concentrations), while 4 µL of DMSO were used as untreated control. The plates were incubated at 37 °C and 250 rpm for 48 h. The experiments were carried out in triplicates, the MIC was determined as the lowest concentration of the compound with no visible bacterial growth.

**MIC Determination on *M. tuberculosis* Strains**

Serial dilutions of drug containing solutions and autoluminescent *M. tuberculosis* AlRa or UAlRv strains broth culture (OD_{600} of 0.3 to 1.0) were prepared. RLU counts from the same batch of triplicate samples were measured according to the designed time points. Ninety-six-well plates were measured as rendering the amount of light by using a Veritas™ Microplate Luminometer Operating Manual (Promega, Madison, WI, USA). MIC_{lux} was determined as the lowest concentration that can inhibit > 90% RLUs compared with that from the untreated controls. The MIC_{lux} of autoluminescent strains were determined by detecting RLUs from these samples as described before [51,52]. The concentrations used were twofold series of dilutions for this purpose, ranging from 0.078 to 20 µg/mL (a total of nine concentrations). The light from each 1.5 mL tube containing total 500 µL culture was detected using GloMax 20/20™ (Promega, Madison, WI, USA). Each above experiment performed in triplicate (three independent experiments) or more by independent persons and from three or more independent cultures.

**MIC Determination on the Rest of the Test Strains**

The determination of antimicrobial activity in vitro was performed by microdilution in Mueller Hinton broth (BD BBL™, 38800 Le Pont-de-Claux, France) for bacterial strains and in RPMI 1640 medium (Sigma-Aldrich), supplemented with 2% glucose for fungi, in accordance with the recommendations of the CLSI [54–56]. The optical density of the inoculum of each strain was measured on a DIN-1 densitometer (Biosan, Riga, Latvia) and adjusted the microorganisms’ density of 0.50 McFarland. Bacterial cells were diluted in Mueller Hinton broth to a final concentration of 10^5 CFU/mL, while *Candida* was diluted in RPMI 1640 medium to a final concentration of 10^3 CFU/mL. The filamentous fungus *M. canis* was incubated until the formation of aerial mycelium (about 5–10 days). Conidia and spores were collected by swab and transferred to physiological saline. The inoculum concentration was counted by hemocytometer and diluted in RPMI 1640 medium to a final concentration of 10^3 CFU/mL. The stock solutions (10 mg/mL) of the test compound were prepared in DMSO, and were used to prepare the serial twofold dilutions with final concentrations ranging from 0.25 to 32 µg/mL (a total of 8 concentrations). The experimental plates were incubated at 36 °C, with the time of incubation depending on the microorganism: 18–20 h for bacterial strains, 24–48 h for *Candida*, and 72–96 h for *M. canis*. The experiments were carried out in triplicates, the MIC was defined as the lowest concentration of a compound at which there was no visible growth of microorganisms.

**3.2.3. Obtaining Spontaneous Drug-Resistant *M. smegmatis* Mutants**

Spontaneous *M. smegmatis* mutants resistant to the tested aminoderivatives of 3-trifluoromethylquinoxaline 1,4-dioxide were obtained as described before [57,58]. Briefly, overnight *M. smegmatis* mc² 155 cultures in the quantity of 1.4 × 10^8 CFU were plated on M290 plates, supplemented with 4 × MICs of the compounds 12–18. A total of 3 plates with each compound were used in the experiments. The plates were incubated at 37 °C until single colonies were visible (5–7 days). The colonies were counted to calculate the frequency of drug-resistance emergence. The colonies were stroked on drug-free M290 plates, and after that re-stroked on the plates with 4 × MIC of the respective compound.
to confirm the drug-resistance. Three mutants resistant to each of the compound were randomly selected for further analysis and whole-genomic sequencing.

3.2.4. *M. smegmatis* Whole-Genomic Sequencing and Analysis

Mycobacterial genomic DNA was isolated from 10 mL by enzymatic lysis as described by Belisle et al. [59], after preliminary isolation, DNA was treated with RNase A (Thermo Fischer Scientific, Waltham, MA, USA) and extracted in the phenol-chloroform-isooamy alcohol solution (25:24:1).

A total of 250 ng genomic DNA was taken for shotgun sequencing library preparation. After DNA sonication on Covaris S220 System (Covaris, Woburn, MA, USA), the size (400–500 b.p.) and quality of fragmented samples were assessed on Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) according to the manufacturer’s manual. NEBNext Ultra II DNA Library Prep Kit (New England Biolabs, Ipswich, MA, USA) was used for pair-ended library preparation, and NEBNext Multiplex Oligos kit for Illumina (96 Index Primers, New England Biolabs) was used for libraries’ indexing. The libraries were quantified by Q Ipswich, MA,uant-iT DNA Assay Kit, High Sensitivity (Thermo Fischer Scientific). DNA sequencing (2 × 125 b.p.) was performed on the HiSeq 2500 platform (Illumina, San Diego, CA, USA) according to the manufacturer’s recommendations.

The obtained reads’ quality was assessed with FastQC (v. 0.11.8) [60], as the quality was good, we proceeded to the assembly without trimming the reads. The reads were aligned to the reference genome (NC_008596.1, PRJNA57701) using the BWA-MEM algorithm [61]. The pileup was generated by mpileup (-B-f) in SAMtools [62]. Single nucleotide variants were called by running mpileup2snp (–min-avg-qual 30 –min-var-freq 0.80 –p-value 0.01 –output-vcf 1 –variants 1) in VarScan (v. 2.3.9) [63]. Annotation was created using vcf_annotate.pl (developed by Natalya Mikheecheva of the Laboratory of Bacterial Genetics, Vavilov Institute of General Genetics, Moscow, Russia). The non-synonymous single nucleotide variants found within open reading frames and absent in the wild-type strain were selected for further analysis. The raw sequencing data (SRA) are publicly available in NCBI GenBank (BioProject ID: PRJNA778794).

3.2.5. Introduction of the Targeted Mutation in MSMEG_4883 Gene

The targeted mutation in *MSMEG_4883* gene of *M. smegmatis* mc2 155 strain was introduced by homologous recombination, using the p2NIL/pGOAL19 suicide vector system [64]. The gene *MSMEG_4883* with flanking arms of approximately 1900 b.p., adjacent to the mutation site was amplified by the Q5 polymerase (New England Biolabs) with primers pN_4883_f (5′-TTTTAAGCTTACCGAGATCGCGTTGAACTT-3′) and pN_4883_r (5′-TTTTTTAATTAACCGACAAGGGAGTACACGAG-3′) with incorporated HindIII and PacI restriction enzymes’ recognition sites, respectively. The amplified products were digested with respective restriction enzymes (Thermo Scientific) and ligated in the p2NIL plasmid. The cassette from pGOAL19 was subsequently cloned in the obtained plasmids at the PacI restriction site. The plasmids were electroporated in *M. smegmatis* mc2 155 cells as described earlier [65] and plated on M290 plates supplemented with kanamycin (50 µg/mL), hygromycin (50 µg/mL) and X-Gal (50 µg/mL), blue single-crossover colonies were selected. Blue colonies were grown overnight in liquid 7H9 medium with OADC, and serial 10-fold dilutions were plated on M290 plates supplemented with X-Gal (50 µg/mL) and sucrose (2% w/v), white double-crossover colonies were selected and tested for Km susceptibility. Target genes were then Sanger-sequenced for a final confirmation of the mutation using the primers pM_4883_f (5′-TTTTTCTGCAGAGGAGGAATTGTTATGAGCATATCGCTGCTGC-3′) and s_4883_r (5′-GACCTTGGATCCGCCGCGTAG-3′). Primer-BLAST [66] was used for primer selection.

3.2.6. Mechanism of Action Determination

Reporter strain *E. coli* BW25113 -pDualrep2 was used as previously described [37]. A total of 1 µL of 20 mg/mL solution of each sample was applied to agar plate containing
a lawn of the reporter strain. After overnight incubation at 37 °C, the plate was scanned by ChemiDoc (Bio-Rad Laboratories, 1000 Alfred Nobel Drive, Hercules, CA, USA) system with two channels including “Cy3-blot” (553/574 nm, green pseudocolor) for RFP fluorescence and “Cy5-blot” (588/633 nm, red pseudocolor) for Katushka2S fluorescence. Induction of expression of Katushka2S is triggered by translation inhibitors, while RFP is up regulated by induction of DNA damage SOS response. 1 µL of levofloxacin (50 µg/mL) and erythromycin (50 µg/mL) were used as positive controls for DNA biosynthesis and ribosome inhibitors, respectively.

4. Conclusions

We describe the synthesis and the profile of antimicrobial properties for the new series of 2-acyl-7-amino-3-trifluoromethylquinoxaline 1,4-dioxide derivatives. The series of 7-amino-3-trifluoromethylquinoxaline 1,4-dioxides was prepared by the nucleophilic substitution of halogen atoms which as in case of 6,7-dihalogeno-3-trifluoromethylquinoxaline 1,4-dioxides proceeds with a good regioselectivity in the position 7. Additionally, these compounds could be obtained by the Beirut reaction between 5-amino-6-halogen substituted benzofuroxan and 1-acyl-3,3,3-trifluoroacetones which also has a high regioselectivity and leads to 2-acyl-7-amino-3-trifluoromethylquinoxaline 1,4-dioxides.

Biological screening of the synthesized 3-trifluoromethylquinoxaline 1,4-dioxides on a panel of bacterial strains and fungi, allowed us to identify several derivatives (12c, 13c, 14c, 15b, 15c, 16c, 17c and 18b) with significant antimicrobial activity comparable to the reference drug, such as DIOX, RIF, AMPH and CIP. The structure-activity relationship revealed a number of important features for the ability of compounds to inhibit the growth of pathogen: the introduction of a halogen atom in the position 6 of the quinoxaline ring increased the antimicrobial activity of the compounds especially on Gram-positive species whereas acyl groups on the position 2 was not so decisive for biological activity. Though a relatively low activity was observed on M. tuberculosis strains, all the compounds except 16a, 16d, 17b, 17d and 18b–c had MIC values (2–8 µg/mL) comparable to those of rifampicin (MIC = 4 µg/mL) on M. smegmatis mc² 155, suggesting these compounds as a basis for further development of antimycobacterial agents. Notably most of the obtained compounds were inactive against tested fungal pathogens such as Candida albicans ATCC 10231 and M. canis B-200, with the exception of 15b (MIC = 4–8 µg/mL compared to AMPH MIC = 0.75 and 2 µg/mL respectively). According to the received data the compound 13c from this series stood out with remarkable activity against most of the tested strains with MIC values in the range of 0.25–10 µg/mL and could be perspective for further evaluation of chemotherapeutic properties and toxicity. It is worth noting, that some of the described compounds were able to inhibit proliferation of breast cancer cell line MCF-7 at submicromolar concentrations [67]. Thus, additional evaluation of cytotoxicity on non-cancer cell lines might be required for a further structure optimization of these derivatives during their development as selective anti-bacterial agents.

The whole-genomic sequences obtained for M. smegmatis spontaneous drug-resistant mutants revealed the high mutagenic potential of 7-aminoderivatives of 2-acyl-3-trifluoromethylquinoxaline 1,4-dioxide, suggesting the same mechanism of DNA-cleavage activity, as described for the previous quinoxaline 1,4-dioxides [42,43], but may still be a clue to a deeper understanding of their redox activation in mycobacterial cells and the mechanisms of drug-resistance emergence. Suggested mechanism of 3-trifluoromethylquinoxaline 1,4-dioxides is also confirmed by upregulation of SOS-response induced reporter pDualrep2: tested compounds and DIOX have demonstrated the same results as other well-studied DNA-damaging agents. However, the noticeable inhibition of protein synthesis was observed for derivatives 13a–c, as well as the absence of correlations between antibacterial activity and the SOS response of bacterial cells for several compounds (12b, 15d, 18d), showing that a more detailed evaluation of the mechanism of action of these compounds and the identification of their intracellular targets are necessary.
The described compounds can be suggested for further development as potential drug candidates with selective antibacterial activity for Gram-positive bacteria, and especially *Mycobacterium* species, based on structural optimization of this promising scaffold.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph15020155/s1, Figures S1–S60: $^1$H and $^{13}$C-NMR spectra of the compounds 6–7a, 7d, 12–18. Table S1: $^{13}$C chemical shifts ($\delta_{C}$, ppm) and characteristic increments ($I_C$) for the $^{13}$C chemical shift differences (relative to 2-propionyl-3-trifluoromethylquinoxaline 1,4-dioxide (7d)) for the piperazinetype group for 14a–c. Figures S61–S87: Copies of HRMS ESI spectra of the products; Figures S88–S112: Copies of HPLC spectra of the products; Figure S113: Nucleotide sequence of MSMEG_4883. The 9 bp repeats are underlined, while the deletion region is highlighted as bold. Table S2: Unique SNPs in quinoxaline-resistant *M. smegmatis* mutants.

**Author Contributions:** Conceptualization and methodology, A.E.S., G.I.B. and D.A.M.; chemical synthesis, G.I.B.; NMR investigation, I.V.I.; in vitro investigation, N.E.G., M.S.A., S.G.F., A.A.V., M.A.K., X.T.; data curation, O.B.B., O.A.D., V.N.D. and T.Z.; writing original draft preparation, review, editing, and visualization, A.E.S., G.I.B. and D.A.M.; resources, D.A.M., A.E.S., V.N.D., T.Z.; supervision, A.E.S., V.N.D. and T.Z.; funding acquisition, D.A.M. and O.A.D.; project administration, D.A.M. and T.Z. All authors have read and agreed to the published version of the manuscript.

**Funding:** The study was partially financially supported by the Joint Russian Science Foundation-National Natural Science Foundation of China Collaboration program (RSF grant number 21-45-00018 to D.A.M., S.G.F., A.A.V., O.B.B. for *M. smegmatis* experiments, and A.E.S., G.I.B. for chemical synthesis; NSFC grant number 82061138019 to T.Z., M.S.A. and X.T. for testing anti-tuberculosis activity), the National Key R&D Program of China 2021YFA1300904 (to T.Z. for pharmaceutical study), and RSF grant number 21-64-00006 (to O.A.D. for analysis on pDualrep2 reported system). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data is contained within the article or supplementary material.

**Acknowledgments:** The authors thank A.M. Korolev for the HRMS ESI spectra, N.M. Maliutina for the HPLC analysis, and Y.N. Lusikov (deceased) for the NMR studies from Gause Institute of New Antibiotics. The authors also thank K.M. Klimina and the Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency for the opportunity to use sequencing resources. The authors also thank I.A. Osterman and D.A. Lukianov from Skolkovo Institute of Science and Technology for discussions and critical feedback.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Cascioferro, S.; Carbone, D.; Parrino, B.; Pecoraro, C.; Giovannetti, E.; Cirrincione, G.; Diana, P. Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm-associated infections. *Chem. Med. Chem.* 2021, 16, 65–80. [CrossRef] [PubMed]

2. Karaiskos, I.; Lagou, S.; Pontikis, K.; Rapti, V.; Poulikou, G. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. *Front. Public Health.* 2019, 7, 151. [CrossRef] [PubMed]

3. Cascioferro, S.; Parrino, B.; Carbone, D.; Pecoraro, C.; Diana, P. Novel strategies in the war against antibiotic resistance. *Future Med. Chem.* 2021, 13, 529–531. [CrossRef] [PubMed]

4. World Health Organization. *World Health Organization Global Tuberculosis Report 2020*; World Health Organization: Geneva, Switzerland, 2020; pp. 1–232.

5. Carta, A.; Corona, P.; Loriga, M. Quinoxaline 1,4-Dioxide: A Versatile Scaffold Endowed with Manifold Activities. *Curr. Med. Chem.* 2005, 12, 2259–2272. [CrossRef] [PubMed]

6. Cheng, G.; Sa, W.; Cao, C.; Guo, L.; Hao, H.; Liu, Z.; Wang, X.; Yuan, Z. Quinoxaline 1,4-Di-N-Oxides: Biological Activities and Mechanisms of Actions. *Front. Pharmacol.* 2016, 7, 64. [CrossRef]

7. Maan, M.K.; Weng, Z.; Dai, M.; Liu, Z.; Hao, H.; Cheng, G.; Wang, Y.; Wang, X.; Huang, L. The Spectrum of Antimicrobial Activity of Cyadox against Pathogens Collected from Pigs, Chicken, and Fish in China. *Antibiotics* 2021, 10, 153. [CrossRef]
8. Carta, A.; Paglietti, G.; Nikookar, M.E.R.; Sanna, P.; Sechi, L.; Zanetti, S. Novel Substituted Quinoxaline 1,4-Dioxides with In Vitro Antimycobacterial and Anticandida Activity. *Eur. J. Med. Chem.* 2002, 37, 355–366. [CrossRef]

9. Constable, P.; Hinchcliff, K.W.; Done, S.; Gruenberg, W. Practical Antimicrobial Therapeutics. *Vet. Med.* 2017, 1, 153–174. [CrossRef]

10. Vernaya, O.I.; Shabatin, V.P.; Shabatina, T.I.; Khvatov, D.I.; Semenov, A.M.; Yudina, T.P.; Danilov, V.S. Cryochemical modification, activity, and toxicity of dioxygen. *Russ. J. Phys. Chem.* 2017, 91, 229–232. [CrossRef]

11. Carta, A.; Loriga, M.; Paglietti, G.; Mattana, A.; Fiori, P.L.; Mollitcotti, P.; Sechi, L.; Zanetti, S. Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides. *Eur. J. Med. Chem.* 2004, 39, 195–203. [CrossRef]

12. Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Synthesis of New Quinoxaline-2-Carboxylate 1,4-Dioxide Derivatives as Anti-Mycobacterium Tuberculosis Agents. *J. Med. Chem.* 2005, 48, 2019–2025. [CrossRef] [PubMed]

13. Ortega, M.; Sainz, Y.; Montoya, M.; Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. Anti-Mycobacterium Tuberculosis Agents Derived from Quinoxaline-2-Carboxilin and Quinoxaline-2-Carbonitrile 1,4-Di-N-Oxide. *Arzneimittelforschung* 2002, 52, 113–119. [CrossRef] [PubMed]

14. Ortega, M.A.; Sainz, Y.; Montoya, M.E.; Ceráin, A.L.D.; Monge, A. Synthesis and Antituberculosis Activity of New 2-Quinoxalinecarbonitrile 1,4-Di-N-Oxides. *Die Pharm.* 1999, 54, 24–25. [CrossRef]

15. Montoya, M.E.; Sainz, Y.; Ortega, M.A.; Ceráin, A.L.D.; Monge, A. Synthesis and Antituberculosis Activity of Some New 2-Quinoxalinecarbonitriles. *Il Farm.* 1998, 53, 57–63. [CrossRef]

16. Vicente, E.; Villar, R.; Pérez-Silanes, S.; Aldana, I.; Goldman, R.C.; Mong, A. Quinoxaline 1,4-Di-N-Oxide and the Potential for Treating Tuberculosis. *Infect. Disord. Drug Targets* 2011, 11, 196–204. [CrossRef]

17. Zarranz, B.; Jaso, A.; Monge, A. Synthesis and Antimycobacterial Activity of New Quinoxaline-2-Carboxamide 1,4-Di-N-Oxide Derivatives. *Bioorg. Med. Chem.* 2003, 11, 2149–2156. [CrossRef]

18. Landelle, G.; Panossian, A.; Leroux, F.R. Trifluoromethyl ethers and -thioethers as tools for medicinal chemistry and drug discovery. *Curr. Top. Med. Chem.* 2014, 14, 941–951. [CrossRef]

19. Zanda, M. Trifluoromethyl Group: An Effective Xenobiotic Function for Peptide Backbone Modification. *New J. Chem.* 2004, 28, 1401–1411. [CrossRef]

20. Santiváñez-Veliz, M.; Pérez-Silanes, S.; Torres, E.; Moreno-Viguri, E. Design and Synthesis of Novel Quinoxaline Derivatives as Potential Candidates for Treatment of Multidrug-Resistant and Latent Tuberculosis. *Bioorg. Med. Chem. Lett.* 2016, 26, 2188–2193. [CrossRef]

21. Buravchenko, G.I.; Scherbakov, A.M.; Dezhnenkova, L.G.; Bykov, E.E.; Solovieva, S.E.; Korlukov, A.A.; Sorokin, D.V.; Fidalgo, L.M.; Shchekotikhin, A.E. Discovery of Derivatives of 6(7)-Amino-3-Phenylquinoxaline-2-Carbonitrile 1,4-Dioxides: Novel, Hypoxia-Selective HIF-1α Inhibitors with Strong Antiestrogenic Potency. *Bioorg. Chem.* 2020, 104, 104324. [CrossRef]

22. Benitez, D.; Cabrera, M.; Hernández, P.; Boiani, L.; Lavaggi, M.L.; Maio, R.D.; Yaluff, G.; Serna, E.; Torres, S.; Ferreira, M.E.; et al. 3-Trifluoromethylquinoloxaline N,N’-Dioxide as Anti-Trypanosomatid Agents. Identification of Optimal Anti-T. Cruzi Agents and Mechanism of Action Studies. *J. Med. Chem.* 2011, 54, 3624–3636. [CrossRef] [PubMed]

23. Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A. Synthesis and Anticancer Activity Evaluation of New 2-Alkylcarbonyl and 2-Benzoyl-3-Trifluoromethylquinoxaline N,N’-Dioxide as Potent Antitumor Agents. *Eur. J. Med. Chem.* 2013, 66, 324–334. [CrossRef] [PubMed]

24. Solano, B.; Junnotula, V.; Marin, A.; Villar, R.; Burguete, A.; Vicente, E.; Pérez-Silanes, S.; Aldana, I.; Monge, A.; Dutta, S.; et al. Synthesis and Biological Evaluation of New 2-Arylcarbonyl-3-Trifluoromethylquinoloxaline 1,4-Di-N-Oxide Derivatives and Their Reduced Analogues. *J. Med. Chem.* 2007, 50, 5485–5492. [CrossRef]

25. Kotovskaya, S.K.; Romanova, S.A.; Charushin, V.N.; Kodess, M.I.; Chupakhin, O.N. 5(6)-Fluoro-6(5)-R-Benzofuroxans: Synthesis and NMR 1H, 13C and 19F Studies. *J. Fluor. Chem.* 2004, 125, 421–428. [CrossRef]

26. Jovené, C.; Jacquet, M.; Marrot, J.; Bourdreux, F.; Kletsy, M.E.; Burov, O.N.; Goncalves, A.-M.; Goumont, R. Revisiting the Synthesis of 4,6-Difluorobenzofuroxan: A Study of Its Reactivity and Access to Fluorinated Quinoxaline Oxides: Revisiting the Synthesis of 4,6-Difluorobenzofuroxan. *J. Org. Chem.* 2014, 80, 6451–6466. [CrossRef]

27. Buravchenko, G.I.; Scherbakov, A.M.; Korlukov, A.A.; Dorovatovskii, P.V.; Shchekotikhin, A.E. Revision of the Regioselectivity of the Beirut Reaction of Monosubstituted Benzofuroxans with Benzoylacetonitrile. 6-Substituted Quinoxaline-2-Carbonitrile 1,4-Dioxides: Structural Characterization and Estimation of Anticancer Activity and Hypoxia Selectivity. *Curr. Org. Synth.* 2020, 17, 29–39. [CrossRef]

28. Hansen, P.E. 13C-NMR of Polycyclic Aromatic Compounds. *A Review. Org. Magn. Reson.* 1979, 12, 109–142. [CrossRef]

29. Imming, P.; Sinning, C.; Meyer, A. Drugs, Their Targets and the Nature and Number of Drug Targets. *Nat. Rev. Drug Discov.* 2006, 5, 821–834. [CrossRef]

30. Buravchenko, G.I.; Scherbakov, A.M.; Dezhnenkova, L.G.; Fidalgo, L.; Shchekotikhin, A.E. Synthesis of 7-Amino-6-Halogeno-3-Phenylquinoloxaline-2-Carbonitrile 1,4-Dioxides: A Way Forward for Targeting Hypoxia and Drug Resistance of Cancer Cells. *RSC Adv.* 2021, 11, 38782–38795. [CrossRef]
32. Pérez-Silanes, S.; Devarappally, G.; Torres, E.; Moreno-Viguri, E.; Aldana, I.; Monge, A.; Crawford, P.W. Cyclic Voltammetric Study of Some Anti-Chagas-Active 1,4-Dioxidoquinaxalin-2-yl Ketone Derivatives. *Helv. Chim. Acta* 2013, 96, 217–227. [CrossRef]

33. Pérez-Silanes, S.; Torres, E.; Arriballa, L.; Varela, J.; Cerecetto, H.; González, M.; Azqueta, A.; Moreno-Viguri, E. Synthesis and Biological Evaluation of Quinoxaline Di-N-Oxide Derivatives with in vitro Trypanocidal Activity. *Bioorg. Med. Chem. Lett.* 2016, 26, 903–906. [CrossRef] [PubMed]

34. Pretsch, E.; Bühlmann, P.; Affolter, C. Structure Determination of Organic Compounds, 4th ed.; Springer: Berlin/Heideberg, Germany, 2009; pp. 154–196.

35. Zhang, H.; Lu, Q.; Zhang, J.; Qu, W.; Xie, S.; Huang, L.; Yuan, Z.; Pan, Y. Discovery of Novel Nitrogenous Heterocyclic-Containing Quinoxaline-1,4-Di-N-Oxides as Potent Activator of Autophagy in M.Tb-Infected Macrophages. *Eur. J. Med. Chem.* 2021, 223, 113657. [CrossRef]

36. Soliman, D.H. Synthesis, Characterization, Anti-Bacterial and Anti-Fungal Activities of New Quinoxaline 1,4-Di-N-Oxide Derivatives. *Int. J. Chem.* 2013, 3, 65–72. [CrossRef]

37. Mazanko, M.S.; Chistyakov, V.A.; Frazdenova, E.V.; Pokudina, I.O.; Churilo, M.N.; Chmyhalo, V.K.; Batyushin, M.M. Dioxidine induces bacterial resistance to antibiotics. *Mol. Gen. Microbiol. Virol.* 2016, 31, 217–232. [CrossRef]

38. Osterman, I.A.; Komarova, E.S.; Shiryaev, D.I.; Korniltsev, I.A.; Khven, I.M.; Lukyanov, D.A.; Tashlitsky, V.N.; Serebryakova, M.V.; et al. Sorting Out Antibiotics’ Mechanisms of Action: A Double Fluorescent Protein Reporter for High-Throughput Screening of Ribosome and DNA Biosynthesis Inhibitors. *Antimicrob. Agents Chemother.* 2016, 60, 7481–7489. [CrossRef]

39. Cheng, G.; Li, B.; Wang, C.; Zhang, H.; Liang, G.; Weng, Z.; Hao, H.; Wang, X.; Liu, Z.; Dai, M.; et al. Systematic and Molecular Basis of the Antibacterial Action of Quinoxaline 1,4-Di-N-Oxides against Escherichia Coli. *PLoS ONE* 2015, 10, e0136450. [CrossRef]

40. Suter, W.; Rosselet, A.; Knüsel, F. Mode of Action of Quinoxin and Substituted Quinoxaline-Di-N-Oxides on Escherichia coli. *Antimicrob. Agents Chemother.* 1978, 13, 770–783. [CrossRef]

41. Ganley, B.; Chowdhury, G.; Bhansali, J.; Daniels, J.S.; Gates, K.S. Redox-Activated, Hypoxia-Selective DNA Cleavage by Quinoxaline 1,4-Di-N-Oxide. *Bioorg. Med. Chem.* 2001, 9, 2399–2401. [CrossRef]

42. Maslov, D.A.; Shur, K.V.; Vatlin, A.A.; Danilenko, V.N. MmpS5–MmpL5 Transporters Provide Mycobacterium smegmatis Resistance to Imidazo[1,2-b][1,2,4,5]Tetrazines. *Pathogens* 2020, 9, 166. [CrossRef]

43. Andries, K.; Villellas, C.; Coeck, N.; Thys, K.; Gevers, T.; Vranckx, L.; Lounis, N.; de Jong, B.C.; Koul, A. Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline. *PLoS ONE* 2014, 9, e102135. [CrossRef] [PubMed]

44. Milano, A.; Pasca, M.R.; Provvedi, R.; Lucarelli, A.P.; Manina, G.; Ribeiro, A.L.d.J.L.; Manganelli, R.; Riccardi, G. Azole Resistance in *Mycobacterium tuberculosis* Is Mediated by the MmpS5–MmpL5 Efflux System. *Tuberculosis* 2009, 89, 84–90. [CrossRef] [PubMed]

45. Li, X.-Z.; Zhang, L.; Naka, H. Efflux Pump-Mediated Intrinsic Drug Resistance in *Mycobacterium smegmatis*. *Antimicrob. Agents Chemother.* 2004, 48, 2415–2423. [CrossRef]

46. Frolova, S.G.; Klimina, K.M.; Kumar, R.; Vatlin, A.A.; Salunke, D.B.; Danilenko, V.N.; Maslov, D.A. Identification of Mutations Conferred by Tryptanthrin Resistance to *Mycobacterium smegmatis*. *Antibiotics* 2021, 10, 6. [CrossRef] [PubMed]

47. Sharp, J.D.; Singh, A.K.; Park, S.T.; Lyubetskaya, A.; Peterson, M.W.; Gomes, A.L.C.; Potluri, L.-P.; Raman, S.; Galagan, J.E.; Husson, R.N. Comprehensive Definition of the SigH Regulon of *Mycobacterium tuberculosis* Reveals Transcriptional Control of Diverse Stress Responses. *PLoS ONE* 2016, 11, e0152145. [CrossRef]

48. Rawat, M.; Av-Gay, Y. Mycothiol-dependent Proteins in Actinomyces. *FEMS Microbiol. Rev.* 2007, 31, 278–292. [CrossRef]

49. Gavaldà, S.; Bardou, F.; Laval, F.; Bon, C.; Malaga, W.; Chalut, C.; Guilhot, C.; Mourey, L.; Daffé, M.; Quémard, A. The Polyketide Synthase Pks13 Catalyzes a Novel Mechanism of Lipid Transfer in Mycobacteria. *Chem. Biol.* 2014, 21, 1660–1669. [CrossRef]

50. Gaughran, R.J.; Picard, J.P.; Kaufman, J.V.R. Contribution to the Chemistry of Benzofuroxan and Benzfurazan Derivatives. *J. Am. Chem. Soc.* 1954, 76, 2233–2236. [CrossRef]

51. Liu, Y.; Gao, Y.; Liu, J.; Tan, Y.; Liu, Z.; Chhotaray, C.; Jiang, H.; Lu, Z.; Chiwala, G.; Wang, S.; et al. The Compound TB47 Is Highly Bactericidal against *Mycobacterium ulcerans* in a Buruli Ulcer Mouse Model. *Nat. Commun.* 2019, 10, 524. [CrossRef]

52. Liu, Q.; Liu, Z.; Sun, C.; Shao, M.; Ma, J.; Wei, X.; Zhang, T.; Li, W.; Ju, J. Discovery and Biosynthesis of Antituberculon, an Antitubercular and Antifungal Cyclodepsipeptide Featuring Vicinal-Dihydroxylated Cinnamic Acyl Chain. *Org. Lett.* 2019, 21, 2634–2638. [CrossRef]

53. Maslov, D.A.; Korotina, A.V.; Shur, K.V.; Vatlin, A.A.; Bekker, O.B.; Tolshchina, S.G.; Ishmetova, R.I.; Ignatenko, N.K.; Ruginov, G.L.; Charushin, V.N.; et al. Synthesis and Antimycobacterial Activity of Imidazo[1,2-b][1,2,4,5]Tetrazines. *Eur. J. Med. Chem.* 2019, 178, 39–47. [CrossRef] [PubMed]

54. CILSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 11th ed.; CILSI Standard M07; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018.

55. CILSI. Reference Method for Broth Dilution Antimicrobial Susceptibility Testing of Yeasts, 4th ed.; CILSI Standard M27; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017.

56. CILSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, 3rd ed.; CILSI Standard M38; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017.
57. Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H.W.H.; Neefs, J.-M.; Winkler, H.; Gestel, J.V.; Timmerman, P.; Zhu, M.; Lee, E.; et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. *Science* **2005**, *307*, 223–227. [CrossRef] [PubMed]

58. O’Malley, T.; Melief, E. Isolation and Characterization of Compound-Resistant Isolates of *Mycobacterium tuberculosis*. *Methods Mol. Biol.* **2015**, *1285*, 317–328. [CrossRef]

59. Belisle, J.T.; Mahaffey, S.B.; Hill, P.J. Isolation of Mycobacterium Species Genomic DNA. In *Mycobacteria Protocols*; Humana Press: Totowa, NJ, USA, 2010; Volume 465, pp. 1–12. [CrossRef]

60. Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data. 2010. Available online: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (accessed on 18 April 2020).

61. Li, H.; Durbin, R. Fast and Accurate Long-Read Alignment with Burrows-Wheeler Transform. *Bioinformatics* **2010**, *26*, 589–595. [CrossRef] [PubMed]

62. Li, H. A Statistical Framework for SNP Calling, Mutation Discovery, Association Mapping and Population Genetical Parameter Estimation from Sequencing Data. *Bioinformatics* **2011**, *27*, 2987–2993. [CrossRef] [PubMed]

63. Koboldt, D.C.; Zhang, Q.; Larson, D.E.; Shen, D.; McLellan, M.D.; Lin, L.; Miller, C.A.; Mardis, E.R.; Ding, L.; Wilson, R.K. VarScan 2: Somatic Mutation and Copy Number Alteration Discovery in Cancer by Exome Sequencing. *Genome Res.* **2012**, *22*, 568–576. [CrossRef]

64. Parish, T.; Stoker, N.G. Use of a Flexible Cassette Method to Generate a Double Unmarked Mycobacterium Tuberculosis TlyA PlcABC Mutant by Gene Replacement. *Microbiology* **2000**, *146*, 1969–1975. [CrossRef]

65. Goude, R.; Parish, T. Electroporation of Mycobacteria. *Methods Mol. Biol.* **2010**, *465*, 203–215. [CrossRef]

66. Ye, J.; Coulouris, G.; Zaretskaya, I.; Cutcutache, I.; Rozen, S.; Madden, T.L. Primer-BLAST: A Tool to Design Target-Specific Primers for Polymerase Chain Reaction. *BMC Bioinform.* **2012**, *13*, 134. [CrossRef]

67. Shchekotikhin, A.E.; Buravchenko, G.I.; Scherbakov, A.M. Method for Inhibiting Tumor Cells with New Derivatives of 3-Trifluoromethylquinoxaline 1,4-Dioxide. Patent RU 2746395, 13 April 2021.